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TGF-β inhibits epithelial cell growth through Smad-dependent induction of a cell cycle 
arrest at G1. During tumor progression, however, many tumor cells escape from TGF-β 
growth suppression due to either functional or genetic disruption of the Smad signaling 
pathway. In late tumor stages, TGF-β stimulates tumor cell proliferation through 
increased cell cycle transition. Although this cellular event is clearly established, the 
molecular mechanisms underlying this phenomenon remain unknown. Here, we show 
that TGF-β stimulation induces cancer cell proliferation via accelerated G1/S phase 
transition. We show that cell proliferation requires induction of the c-Myc oncogene, 
and this is paralleled by upregulation of D-type cyclins and their corresponding CdKs. 
TGF-β induces c-Myc expression on the level of promoter regulation through induction 
of the c-Myc/TIE element, which has previously been reported as the core element for 
repression of c-Myc in growth inhibited cells.  
 
Mechanistically, TGF-β induces c-Myc promoter activation through the calcium 
responsive NFAT transcription factor family. We show that TGF-β induces expression 
and subsequent nuclear accumulation of NFATc1 and NFATc2 in cancer cells. NFAT 
proteins then bind to and displace Smad repressor complexes from the c-Myc/TIE to 
induce the c-Myc promoter transactivation and expression. c-Myc induction, on the 
other hand, is essential for subsequent cyclin upregulation and stimulation of G1/S 
phase transition in cancer. Thus, this study uncovers a key signaling and transcription 
pathway in TGF-β growth stimulation and identifies the NFAT transcription factor family 
as essential mediators of this function. From the medical point of view this study not 
only help to better understand the mechanisms underlying TGF-β growth promotion in 
cancer, but also provide a platform for novel options in the treatment of pancreatic 




molecules that target the NFAT pathway more specifically in tumor cells. Future studies 
will show whether specific targeting of the NFAT system in tumor cells is a promising 
new strategy in the treatment of pancreatic cancer and in particular in those with high 







In normalen epithelialen Zellen und in frühen Tumorstadien bewirkt TGF-β eine 
starke Tumorsuppression, die v.a. auf der Smad vermittelten Induktion eines 
Zellzyklus-Arrests beruht. Während der Tumorprogression verlieren jedoch sehr 
viele Tumorzellen ihre Fähigkeit auf einen TGF-β Stimulus mit einer 
Wachstumshemmung zu antworten. Dies kann sowohl in genetischen Alterationen 
der TGF-β/Smad Signalkaskade, als auch in funktionellen oder epigenetischen 
Veränderungen dieses Signalweges oder wichtiger Interaktionspartner begründet 
sein. In späten Tumorstadien stimuliert TGF-β dann sogar das Wachstum 
epithelialer Zellen, obgleich die zugrundeliegenden molekularen Mechanismen 
nur unzureichend verstanden sind. Im Rahmen der vorliegenden Untersuchung 
konnten wir zeigen, dass TGF-β das Wachstum von Pankreaskarzinomzellen durch 
Induktion einer  gesteigerten Zellzyklus-Progression stimuliert, was mit einer 
Zunahme der Expression von D-Typ Zyklinen und ihrer Aktivatoren einhergeht. 
Von zentraler Bedeutung ist hierbei die Promotoraktivierung und Induktion des 
mitogenen Transkriptionsfaktors c-Myc.  
 
Wir konnten zeigen, dass die Induktion von c-Myc nicht nur essentiell für die 
konsekutive Zellzyklus-Progression ist, sondern auch von einer vorangehenden 
Induktion der NFAT Transkriptionsfaktoren abhängt. TGF-β induziert Smad-
unabhängig die Expression und nukleäre Akkumulation von NFATc1 und NFATc2, 
welche anschlieβend am TIE-Element des proximalen c-Myc Promotors binden. 
Das TIE Element wurde in früheren Studien als „TGF-β-inhibitory element“ 
beschrieben und ist für die TGF-β vermittelte Repression des c-Myc Promotors 
und der Vermittlung einer Wachstumshemmung in epithelialen Zellen wichtig. In 




Promotors zur Verdrängung DNA-bindender Smad3-Repressorkomplexe und 
anschlieβenden Induktion der c-Myc Transkription, G1-Progression und 
Proliferation. Dieser neue Mechanismus der TGF-β-Wachstumsregulation ist von 
zentraler Bedeutung für das phänotypische Verhalten von Pankreaskarzinomzellen 
und streng abhängig von der sequentiellen Induktion der pro-proliferativen 
Transkriptionsfaktoren NFAT und c-Myc. Diese Arbeit verdeutlicht auch die Rolle 
Smad-unabhängiger transkriptionell regulatierter Mechanismen im 
Pankreaskarzinom und untermauert eine wichtige Funktion der NFAT 
Transkriptionsfaktoren in der Karzinogenese epithelialer Tumoren. Letztlich liefert 
unsere Untersuchung erste Hinweise auf ein therapeutisches Potenzial der 












1.1 THE PLURIPOTENCY OF TRANSFORMING GROWTH 
FACTOR- BETA 
 
The transforming growth factor beta (TGF-β) signalling pathway is a key player in 
metazoan biology, and its misregulation can result in tumor development (Levy et 
al., 2006). The regulatory cytokine TGF-β exerts tumor-suppressive effects that 
cancer cell must elude for malignant evolution (Cui et al., 1996; Massague et al., 
2000). Yet, paradoxically, TGF-β also modulates processes such as cell invasion and 
proliferation, immune regulation, and microenvironment modification that cancer 
cells may exploit to their advantage (Massague et al., 2008). Consequently, the 
output of a TGF-β response is highly contextual throughout development, across 
different tissues, and also in cancer. The mechanistic basis and clinical relevance of 
TGF-β's role in cancer is becoming increasingly clear, paving the way for a better 
understanding of the complexity and therapeutic potential of this pathway.  
  
1.2 TGF-ΒETA SIGNALLING ACTIVATION 
 
TGF-β signals through two classes of receptors, the TGF-β type I receptor (TβRI) 
and the TGF-β type II receptor (TβRII). Endoglin and betaglican, also called 
accessory receptors, bind to TGF-β with low affinity and present it to the TβRI and 
TβRII (Shi et al., 2003). Type I and II receptors are serine/threonine kinase 
receptors that form a heterodimeric complex upon TGF-β binding. TGF-β interacts 
with the ectodomain of the TβRII and allows the subsequent incorporation of the 
TβRI generating a ligand-receptor complex formed by a ligand dimer. The TβRII 
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appears to be a constitutively active kinase that, when the ligand–receptor 
complex is formed, phosphorylates a characteristic SGSGSG sequence, called the 
GS domain, present in the type I receptor. Phosphorylation of the TβRI GS domain 
leads to the activation of its kinase and turns the GS region into a Smad binding 
site. Once activated by the TβRII, the TβRI initiates activation of distinct 
intracellular signalling pathways, most notably the Smad signalling cascade 
(Seoane et al., 2006). 
 
1.3 THE SMAD SIGNALLING PATHWAY  IN  NORMAL AND 
MALIGNANT EPITHELIAL CELLS 
 
Smad proteins are central mediators of TGF-β signalling. They can be classified 
into three subtypes, e.g. receptor-regulated Smads (R-Smads), common-partner 
Smads (Co-Smads), and inhibitory Smads (I-Smads) (Miyazono et al., 2000). Of the 
eight different Smad proteins in mammals, Smad2 and Smad3 serve as R-Smads 
for TGF-β signalling pathways, Smad4 acts as a Co-Smad (Moustakas et al., 2001) 
and Smad7 functions as an I-Smad for TGF-β signalling (Nakao et al., 1997). Smad 
proteins have conserved N- and C-terminal regions, termed the MH1 and MH2 
domains, respectively. The MH1 and MH2 domains are bridged by linker regions. 
In all three subtypes of Smads, MH2 domains are highly conserved (Miyazono et 
al., 2000). In contrast, MH1 domains are conserved in R-Smads and Co-Smads, 
whereas the N-terminal regions of I-Smads are highly divergent from those of R- 
and Co-Smads (Nakayama et al., 2001).  
 
R-Smads are anchored to the plasma membrane through various molecules, 
among which Smad anchor for receptor activation (SARA) has been most 
extensively studied (Tsukazaki et al., 1998). SARA has a FYVE domain, which is 
responsible for binding to phosphatidyl inositol-3-phosphate in the plasma 
membrane. SARA preferentially binds to the MH2 domains of Smad2 and Smad3, 
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but not to those of other Smads. SARA forms a dimer in cells, and anchors two 
molecules of Smad2/3 to the plasma membrane, which may be important for 
efficient activation of R-Smads by the hetero-tetrameric TβRII and TβRI complexes 
(Wu et al., 2000). The activated TβR-I kinase phosphorylates the last two serine 
residues at the C-terminal Ser-Ser-X-Ser motif of R-Smads. R-Smads then form 
heteromeric complexes with Co-Smad through their MH2 domains, and 
translocate into the nucleus (Shi et al., 2003). Although the exact structures of the 
R-Smad/Co-Smad heteromers have not been fully determined, a heterotrimer 
composed of two molecules of R-Smads and one molecule of Co-Smad, or a 
hetero-dimer composed of one molecule each of R-Smad and Co-Smad, has been 
proposed (Itoh et al., 2000). R-Smads and Co-Smads shuttle between the nucleus 
and cytoplasm.  
 
Nuclear localization signals (NLSs) in the MH1 domains of R-Smads play pivotal 
roles in translocation of Smads into the nucleus, whereas nuclear export signals 
(NESs) in the MH2 domains of R-Smads and those in the linker region of Co-Smads 
are responsible for nuclear export of the complex (Reguly et al., 2003). In the 
nucleus, the R-Smad-Co-Smad heteromers interact with various transcription 
factors and transcriptional co-activators or co-repressors, resulting in transduction 
of a wide variety of intracellular signals in target cells (Wrana et al., 2000). R-
Smads and Co-Smads also directly bind to specific DNA sequences, although with 
relatively low affinities. Thus, Smads and other transcription factors cooperatively 
regulate transcription of target genes through binding to their promoters. 
Transcriptional co-activators, including p300, CBP, and P/CAF, contain histone 
acetyl transferase (HAT) domains (Janknecht et al., 1998; Feng et al., 1998; Itoh et 
al., 2000). Through acetylation of histones and probably other proteins, these 
transcriptional co-activators help Smads activate the transcription of target genes 
(Massagué et al., 2000; Derynck et al., 1998). 
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1.4 GENETIC ALTERATIONS OF THE SMAD SIGNALLING 
PATHWAY 
 
Genetic alterations of this simple TGF-β signalling pathway are frequently found in 
somatic and heritable disorders as well as in various tumor entities (Gold et al., 
1999). Inactivating mutations of the type-II receptor, for instance, have been 
reported in colorectal, gastric and endometrial carcinomas and in association with 
a more aggressive phenotype (Markowitz et al., 1995; Teicher et al., 2001). In 
addition, more than half of pancreatic carcinomas and approximately one third of 
colorectal carcinomas harbor inactivating mutations of the Smad4 gene based on 
homozygous deletion or intragenic mutation (Moore et al., 2001; Takagi et al., 
1996). In many cases, genetic loss of Smad4 causes disrupted nuclear-cytoplasmic 
shuttling of Smad complexes and thus renders tumor cells insensitive to nearly all 
TGF-β regulated transcriptional responses, including those associated with growth 
inhibition (Miyaki et al., 2003). Genetic alterations of the Smad4 gene are also 
found in familial juvenile polyposis, an autosomal dominant disease characterized 
by predisposition to gastrointestinal polyps and cancer (Huang et al., 2009; Chow 
et al., 2005). In this syndrome, polyps are formed by inactivation of the Smad4 
gene through germline mutation and loss of the unaffected wildtype allele (Chow 
et al., 2005).  
 
Together, disruption of TGF-β-Smad signalling through inactivating mutations are 
commonly observed in different malignancies and is closely associated with the 
loss of tumor suppression by TGF-β. Importantly, however, signal transduction and 
target gene transcription by the Smads is not only affected by genetic alterations 
within the pathway, but also through signalling crosstalk interactions (Bierie et al., 
2006). In fact, at one level or another, essentially all major tumor suppressor and 
oncogenic signalling pathways can converge on Smads as a mode for signal 
integration and thus can positively or negatively influence Smad-mediated 
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transcription. Inputs by other pathways occur at the level of receptor activation, R-
Smad complex formation with Co-Smad4, or at the level of the nuclear 
translocation of pre-formed R-Smad/Co-Smad complexes.  
 
Crosstalk between Smads and distinct mitogen-activated protein kinases (MAP 
kinases) such as extracellular signal regulated kinases (Erk) 1 and 2 and the stress-
activated protein kinases, Jun N-terminal kinase (JNK) and p38, are of particular 
interest in carcinogenesis (Hocevar et al., 1999). For instance, mutational 
activation of MAP kinase pathway is frequently found in human carcinomas, most 
notably via the activation of oncogenic Ras, an upstream activator of the 
proliferative Raf-Mek-Erk signalling cascade, which is an early event in many 
tumors, such as pancreatic cancer (Giehl et al., 2000). Persistent activation of MAP 
kinase pathways by oncogenic Ras inhibits Smad signalling through Erk mediated 
phosphorylation of MAP kinase sites within the linker region of Smad2 and Smad3, 
thereby blocking the complex formation with Smad4 (Kretzschmar et al., 1999).  
 
The linker region is a critical phosphorylation site for several kinase regulated 
signalling pathways. For instance, Smad proteins contain multiple phosphorylation 
sites for Ca2+/calmodulin dependent protein kinase II (CamKII) and protein kinase 
C (PKC), which phosphorylate Smad2 and Smad3 and thereby inhibit either the 
nuclear translocation or the DNA binding of Smads (Wicks et al., 2000). In contrast, 
signalling crosstalk with JNK or MEKK1, an upstream activator of the JNK pathway, 
has been shown to facilitate the nuclear accumulation of Smad complexes and 
thereby accelerate Smad-signalling in cancer cells.  
 
Together, the Smad signalling transduction pathway is commonly altered by either 
genetic alterations or crosstalk interactions with cascades that play important 
functions in gene regulation during carcinogenesis. 
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1.5 SMAD-INDEPENDENT SIGNALLING IN NORMAL AND 
MALIGNANT EPITHELIAL CELLS 
 
Although Smad signalling is considered the central TGF-β signalling pathway, many 
studies have revealed additional effectors in downstream signalling that 
fundamentally affect the transcriptional response to TGF-β (Moustakas et al., 
2001; Warna et al., 2000). Based on their mode of actions, the non-Smad proteins 
are categorized in three different groups: (i) non-Smad signalling pathways that 
directly modify Smad function; (ii) non-Smad proteins whose function is directly 
modulated by Smads and which transmit signals to other pathways; and (iii) non-
Smad proteins that directly interact with or become phosphorylated by TGF-β 
receptors but do not necessarily affect the function of Smads.  
 
Best studied non-Smad proteins are members of the MAPK family (Yue et al., 
2000). TGF-β-induced activation of Erk, JNK and p38 MAPK kinase pathways 
causes a broad spectrum of cellular responses including cell proliferation, 
apoptosis and differentiation (Lehmann et al., 2000). Depending on cellular 
activation, induction of MAPKs can occur in a Smad-dependent or Smad-
independent fashion (Engel et al., 1999). Smad-independent activation of p38 
MAPK, for instance, has recently been demonstrated in Smad4-deficient cells and 
in cells with mutated TGF-β type-I receptors, defective in Smad activation (Yu et 
al., 2002). Following TGF-β stimulation, MAPKs can then regulate gene 
transcription through either direct activation of specific transcription factors, such 
as Elk or AP-1, or through crosstalk interaction with the Smads resulting in positive 
or negative effects on TGF-β-mediated transcription.  
 
The group of receptor-induced non-Smads comprises important regulatory 
FKBP12 (Wang et al., 1996), TRIP-1 and the B subunit of the protein phosphatase 
2A, PP2A (Griswold-Prenner et al., 1998; Petritsch et al., 2000) each of which have 
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been identified by their specific interaction with the TGF-β type-I receptor. PP2A 
consists of a catalytic C domain and two regulatory subunits, termed subunits A 
and B. The regulatory B subunit is one example among other WD40 proteins, that 
can modulate TGF-β-induced transcription (STRIP1, STRAP) or links TGF-β to 
modulate translation (Strip1, EIF2alpha). Upon TGF-β-binding, the B subunit of 
PP2A associates with the activated type-I receptor, enhances PP2A activity and 
allows the recruitment of p70S6K, a kinase with a key role in translational control 
and cell-cycle progression. Another important family of TGF-β effector proteins is 
members of the Rho-like GTPases which have emerged as alternative components 
of intracellular signalling pathway originating from the TGF-β receptor. There is 
much evidence that the Rho family of proteins mediates many cytoskeletal effects 
as well as cell motility, and maintaining focal contacts and contractile stress fibers.  
 
It has been reported that RhoA plays a central role in TGF-β-induced epithelial to 
mesenchymal transdifferentiation, EMT, (Bhowmick et al., 2001) and that TGF-β 
can stimulate cell motility and cytoskeletal organization via activation of RhoA. 
Some of these effects might be regulated on the transcriptional level, some other 
occur indirectly and through interaction with other signalling cascades. In human 
hepatoma cells, TGF-β activates protein kinase C (PKC) (Miyazaki et al., 2004; 
Sakaguchi et al., 2004). PKC then phosphorylates the regulatory protein 
S100C/A11, which translocates to the nucleus to recruit Sp1 to the promoters of 
the p15 and p21 genes. This pathway is very similar to the parallel Smad pathway, 
which also induces these genes through interactions with Sp1 (Feng et al., 2000; 
Pardali et al., 2000). Together, many non-Smad signalling proteins modulate the 
activity of the Smad pathway and therefore, can potentially affect gene regulation 
by TGF-β in both normal and malignant cells.  
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1.6 TGF-ΒETA GROWTH CONTROL IN NORMAL AND 
MALIGNANT CELLS 
 
Most pertinent to our understanding the role of TGF-β in carcinoma development 
is the fact that TGF-β is a potent inducer of growth inhibition in several cell types, 
including epithelial cells. One key event that leads to TGF-β induced growth arrest 





depending on the cell type (Massague 2008). The inhibitor p21
CIP1
 interacts with 
complexes of CdK2 and cyclin A or cyclin E and thereby inhibits CdK2 activity, 
preventing progression of the cell cycle. By contrast, p15
INK4B
 interacts with and 
inactivates CdK4 and CdK6, or associates with cyclin D complexes of CdK4 or CdK6 
(Warner et al., 1999). The latter interaction not only inactivates the catalytic 
activity of these CdKs but also displaces p21
CIP1
 or the related p27
KIP1
 from these 
complexes, allowing them to bind to and inactivate the CdK2 complexes with 




 expression in response to TGF-β is 
brought about by Smad-mediated transcriptional activation.  
 
In contrast to many TGF-β responses that are mediated by Smad3 and Smad4, a 
heteromeric complex of Smad2, Smad3 and Smad4 induces transcription by 
interacting with Sp1 at the p15
INK4B
 or the p21
CIP1
 promoter (Feng et al., 2000; Li et 
al., 1995). Consequently, the Smad complex recruits the coactivator CBP/p300 into 
the complex and strongly potentiates the transcriptional activity of Sp1, which 




 genes. Additional mechanisms also 
contribute to TGF-β–mediated growth arrest, again depending on the cell type. 
Most important, TGF-β inhibits the expression of the c-Myc oncogene. High levels 
of c-Myc render the cells resistant to the growth inhibitory activity of TGF-β, and 





expression (Seoane et al., 2001). The interaction of c-Myc in a complex at the 
p15
INK4B
 promoter correlates with transcriptional repression; TGF-β induced down 
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regulation of c-Myc thus allows the repression of cell by TGF-β–induced 
transcription of p15
INK4B
 through Smads. Chen and coworkers have recently 
identified a TGF-β inhibitory element of the c-myc promoter which is responsible 
for TGF-β-induced repression of the c-Myc (Chen et al., 2002). This group has 
further demonstrated that TGF-β-induced c-Myc repression can be mediated by 
interaction of Smad3, p107 and members of the E2F transcription factor family. 
E2F4 and E2F5 associate with p107 and assemble a complex with Smad3 in the 
cytoplasm that translocates into the nucleus following TGF-β receptor activation 
(Chen et al., 2002). Increasing evidence also suggests a role for the TGF-β-
inducible non-Smad transcription factors in TGF-β-induced cell growth inhibition.  
 
Most recently, our laboratory has explored a novel mechanism in c-Myc 
repression that was mediated through a Smad3-TIEG2 complex. Following TGF-β 
stimulation, nuclear TIEG2 interacts with Smad3 via its DNA-binding zinc-finger 
domain and co-operatively represses myc-transcription from the TGF-β inhibitory 
element (TIE) of the human c-myc promoter. We demonstrated that the TIE 
element comprises a TIEG2-binding site and an adjacent Smad binding element, 
both of which were integral in conferring full promoter repression by TGF-β 
(Ellenrieder et al., 2002). Mutational inactivation of either the TIEG- or the Smad 
binding element significantly lowered TGF-β-responsiveness of the TIE element. 
Moreover, disruption of KLF11-Smad3 interaction or artifical knockdown of 
endogenous KLF11 expression strongly diminished Smad3-TIE binding, caused loss 
of c-Myc repression and rendered epithelial cells less sensitive for TGF-β-induced 
cell growth inhibition (Ellenrieder et al., 2008). Together, new data clearly 
demonstrate that Smad and TIEG2 effector proteins synergize in TGF-β-induced 
cell growth inhibition through co-operative repression of the c-Myc proto-
oncogene.  
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1.7 MECHANISMS UNDERLYING THE DUAL ROLE OF TGF-
ΒETA DURING TUMORIGENESIS 
 
Similar to its effects on normal epithelial cells, TGF-β inhibits tumor growth at 
early tumor stages. As the tumor progresses, however, genetic disturbances of the 
TGF-β-signalling pathway may occur and render the tumor cells insensitive to TGF-
β-induced growth inhibition. It is abundantly clear that loss-of-function mutation 
of TGF-β signalling components is one route towards loss of growth control in 
cancer (Massague et al., 2008). On the other, it became also clear, that many 
tumor cells become refractile to the growth inhibitory effects of TGF-β despite 
lack of genetic alterations of the TGF-β signalling pathway. These tumor cells are 
of particular interest in tumor research as they frequently respond to TGF-β with 
increased migration and proliferation, and severe phenotypic changes described 
as an epithelial-to-mesenchymal transdifferentiation (Seoane et al., 2008; 
Muraoka-Cook et al., 2005).   
 
During tumor progression, crosstalk interactions between Smads and oncogenic 
signalling pathways occur at different cellular levels and in all cellular 
compartments (Ellenrieder et al., 2001). For instance, altered activation of 
oncogenic signalling cascades such as the proliferative Ras-Raf-Erk MAPK pathway 
dramatically affects both the constellation and the activation status of Smad-
interacting transcription factors in the nucleus and this influences the 
transcriptional reponse to TGF-β in tumor cells. A good example came from our 
laboratory showing that Smad3/TIEG2 mediated repression of c-myc is blocked in 
pancreatic cancer cells with oncogenic Ras mutations. We have further 
characterized this phenomenon and identified a novel mechanism involved in the 
loss of TGF-β-growth inhibition. We could show that in pancreatic cancer cells with 
oncogenic Ras mutation, hypersensitive Erk MAPK phosphorylates TIEG2 at four 
serine/threonine sites within the linker region between the R1 and R2 repression 
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domains and subsequently inhibits binding of the Sin3A corepressor (Ellenrieder et 
al., 2002, Ellenrieder et al., 2004). Erk MAPK induced disruption of Sin3A 
corepressor binding results in loss of TIEG2-mediated c-myc repression, an effect 
that can be prevented by introduction of Erk-insensitive TIEG2 mutants. Thus, 
results from our laboratory together with observations from other groups 
contributed to a better understanding of how inactivation of Smad partnering 
transcription factors affect Smad-mediated transcription and anti-proliferation. 
Together, these studies suggested that Smad inactivation is a key process during in 
the loss of growth suppression by TGF-β in cancer (Massague et al 2000).  
 
Moreover, crosstalk with oncogenic signalling pathways might also play roles in 
TGF-β-stimulated tumor progression. Prominent examples are again mitogen-
activated protein (MAP) kinase pathways, which are commonly observed in tumor 
cells, and the activation of which is required for TGF-β-induced expression of 
extracellular matrix degrading proteases. TGF-β often promotes tumor 
progression through induction of an epithelial-mesenchymal transdifferentiation 
of tumor cells (Oft et al., 1996, Ellenrieder et al., 2001). EMT is a characteristical 
feature of highly invasive tumor cells and result from interactions of Smads with 
oncogenic signalling pathways members. Several signalling pathways have already 
been identified to play role in TGF-β-induced EMT. Of particular relevance are 
again crosstalks with Jagged/Notch signalling PI3K-AKT signalling, RhoA, Rac1 and 
p38MAPK (Zavadil et al., 2004, Bakin et al., 2002; Horowitz et al., 2004). The 
requirement for an intact Smad signalling was demonstrated by using a mutant 
TGβRI construct that failed to bind Smads, but can still activate MAPK pathways.  
Despite observations that Ras exerts inactivating phosphorylation on Smads, in 
case of EMT synergy between TGF-β and Ras-Raf-MAPK pathways to promote EMT 
was reported and observed by our group (Ellenrieder et al., 2001). Especially in 
pancreatic tumors a high number of activating mutations in Ki-Ras oncogene can 
be observed. Together with an intact TGF-β signalling pathway, this might account 
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for the migratory capacities of pancreatic adenocarcinoma in many patients. 
However, in contrast to the mechanisms responsible for EMT, migration and 
invasion, there is only very limited information about those mechanisms that 
mediate cell proliferation by TGF-β.  
 
In fact, it is still unclear whether TGF-β utilizes the Smad pathway to mediate 
growth in advanced tumor stages or whether alternative signalling and 
transcription pathways are more important during gene regulation in cancer 
growth.   
     AIMS 
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2 AIMS OF THE STUDY 
 
The role of TGF-β in cancer biology is complex and involves aspects of tumor 
suppression as well as tumor promotion. Overexpression of TGF-β expression 
in the tumor cells ecpecially in pancreatic cancer have seen and which creates 
a tumor micro-environment that stimulates both tumor growth and 
metastasis. The diametrically opposed roles of TGF-β as a potent tumor 
suppressor and as a tumor promoter has gained widespread acceptance in 
recent years.  
 
In contrast to the mechanisms underlying tumor cell migration and invasion, 
the signalling and transcription pathways involved in the TGF-β switch from a 
growth suppressor to a strong promoter of tumor cell growth are only 
marginally understood. We therefore conducted this study to analyse how 
TGF-β stimulates pancreatic cancer cells to proliferate. 
 
In particular we addressed the following specific questions: 
 
1. Does TGF-β induce cell proliferation in cancer? 
 
2. Does TGF-β stimulate cancer cell proliferation on the level of gene       
 transcription? 
 
3. Which signalling and transcriptional pathways confer cancer growth 
promotion  
 by TGF-β?  
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3. MATERIALS AND METHODS 
 
3.1 MATERIALS 
3.1.1 Cell Lines 
 
1. HaCaT (Human keratinocyte cell line ) 
2. Panc1 (human pancreactic cancer cell line) 
3. 8988t (human pancreactic cancer cell line) 
 
3.1.2 Chemical reagents and general materials 
 
Reagent       Source  
Cell strainer (70 μM)     Falcon  
2 ml cryotubes      Greiner bio-one  
Disposable needles, cuvettes & syringes  Greiner bio-one  
Glasswares      Schott  
Nitrocellulose membrane Schleicher & Schuell  
Polypropylene tubes     Greiner bio-one  
Parafilm       Greiner bio-one  
Pipette tips      Eppendorf  
Pipettes       Sarstedt  
Röntgen film (13x18 cm, BioMax)   Amersham  
Sterile filters (0.2 μM/ 0.45 μM)   Schleicher  
Tissue culture plates     Greiner bio-one 
Tissue culture flask (50, 250, 500 ml)   Greiner bio-one  
Tissue culture dish (60 mm, 90 mm)   Greiner bio-one  
Tubes (1.5 & 2 ml) Sarstedt    Eppendorf  
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Whatmann paper     Schleicher & Schuell  
12 well cell culture plates    Nunc 
6 & 24 well cell culture plates    Nunc  
6 mm Petri dishes     Nunc  
 
3.1.3 Chemical reagents 
 
Chemicals      Source 
Acetone       Carl Roth  
Acrylamid solution     Carl Roth  
Agar       Carl Roth  
Agarose       Sigma-Aldrich  
Ampicillin      Sigma 
APS Merck      Eurolab  
β-Mercaptoethanol     Carl Roth  
BioRad protein assay      BioRad  
Bromophenol blue      Sigma 
Bovine serum albumin (BSA)    Sigma  
Calcium chloride [CaCl2]    Carl Roth  
Cyclosporin A [CsA]     Novartis Pharma  
dNTPs       MBI-Fermentas  
DTT       Carl Roth  
ECL chemiluminiscence    Amersham 
EDTA       Carl Roth  
EGTA       Sigma-Aldrich  
Ethanol       Carl Roth  
Ethidium Bromide [EtBr]    Sigma-Aldrich  
Formaldehyde      Carl Roth  
Forskolin      Calbiochem  
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ECL chemiluminescence kit    Pierce & GE healthcare 
Gene Ruler™ 100bp ladder    MBI Fermentas 
Glycerin (87%)      Carl Roth  
Glycine       Carl Roth  
Hepes       Carl Roth 
Hydrochloric acid [HCl]     Merck Eurolab 
Isoamylalcohol       Carl Roth 
Isopropanol      Carl Roth 
Leupeptin hydrochloride    Roche  
Lithium chloride     Sigma-Aldrich 
Milk powder      Sigma 
Magnesium acetate      Sigma-Aldrich 
Magnesium chloride     Carl Roth 
Magnesium sulfate     Carl Roth 
Manganese chloride      Fluka 
Methanol       Carl Roth 
Phenol       Carl Roth 
PMSF       Roche 
Proteinase K      Sigma-Aldrich         
Protein A sepharose     Upstate 
Protein G sepharose     Upstate 
Polyacrylamide      Applichem 
Ponceau Red      Sigma-Aldrich 
Potassium acetate     Carl Roth 
Potassium chloride     Sigma-Aldrich 
Potassium dihydrogen phosphate   Sigma-Aldrich 
Potassium hydrogen phosphate   Sigma-Aldrich 
Potassium hydroxide     Carl Roth 
Propidiumiodide      Sigma-Aldrich 
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Protease inhibitor tablet (complete mini)  Roche  
Sodium azide      Sigma 
Sodium citrate      Sigma                
Sodium acetate      Merck Eurolab 
Sodium carbonate     Carl Roth 
Sodium chloride     Carl Roth 
Sodium fluoride     Sigma-Aldrich 
Sodium hydrogen phosphate    Merck Eurolab 
Sodium hydroxide     Carl Roth 
SDS       Carl Roth 
TEMED       Carl Roth  
TGF-β       Tebu-Bio 
 
3.1.4 Transfection reagents 
 
Reagents      Source  
Transfast for plasmid transfection    Promega 
Transmessenger for SiRNA transfection   Qiagen  
SilentFect for SiRNA transfection    Bio-Rad 
 
 
3.1.5 Radioactive chemical 
           
Reagents      Source 
 [methyl-
3









Hardware      Manufacturer  
Autoclave      Stiefenhofer 
Bacterial shaker     New Brunswick Scientific 
Balance machine     Sartorius 
Cold centrifuge      Eppendorf 
FACS Calibur      Becton Dickinson 
Gel camera      Stratagene 
Heating blocks      Eppendorf 
Ice machines      Genheimer 
Laminar hoods      Heraeus 
Liquid nitrogen tank     Tec-lab 
Luminometer      Berthold 
Microliter pipettes     Eppendorf 
Microcentrifuge     Eppendorf 
Microscope      Ziess 
pH meter      Ingold 
Refrigerators (-20°C; -80°C)    Privileg and Bosch 
Shaking incubator     Eppendorf  
Spectrophotometer     Amersham Pharmacia  
Vortexer      Eppendorf  
Waterbath      Eppendorf  
Western blot apparatus    Hoefer  
Real-time PCR machine    ABI Prism 7000  
DL Ready
TM









Dual Luciferase Reporter Assay Kit    Promega 
RNeasy Mini Kit      Qiagen 
Plasmid-DNA isolation kit (Maxi)   Qiagen 
PCR purification kit     Qiagen 
 
3.1.8 PCR reagents 
 
Reagents        Source 
dNTPs        MBI Fermentas  
MgCl2        MBI Fermentas 
10X Buffer        MBI Fermentas  
Taq polymerase       MBI Fermentas 
 
3.1.9 Real-time PCR primers for cDNA 
 
c-Myc 
5’ GCTCCTGGCAAAAGGTCAGA 3 ’ 
5’ CAGTGGGCTGTGAGGAGGTT 3’ 
 
NFATc1 
5’ TGCAAGCCGAATTCTCTGG 3’ 
5’ GGGAAGGTAGGTGAAACGCTG 3’ 
 
NFATc2 
5’ GTTCCTACCCCACAGTCATTCAG 3’ 
5’ CCCGCAGGTAATACTTCCTTTTG 3’ 





5’ CACCGTGTTCTTCGACATCA 3’ 
5’ AGCA TTTGCCATGGACAAGAT 3’ 
 
XS-13 
5’ GTCGGAGGAGTCGGACGA 3’ 
5’ GCCTTTATTTCCTTGTTTTGCAAA 3’ 
 
 3.1.10 Real-time primers for ChIP 
 
c-Myc-4 
5’ AGGGCTTCTCAGAGGCTTG 3’ 
5’ TGCCTCTCGCTGGAATTACT 3’ 
 
c-Myc 17 
5’ GAGGGATCGCGCTGAGTAT 3’ 




#2 - 5’ GCUGAUGAGCGGAUCCUUATT 3’ 
#3 - 5’ CCAUUAAACAGGAGCAGAATT 3’ 
 
NFATc1 
#1 - 5’ CCAUUAAACAGGAGCAGAATT 3’  
#2 - 5’ GCUGAUGAGCGGAUCCUUATT 3’ 
 




 #1 - 5’ GCAUCCGCUGUUCCAGUGGUTT 3’ 
#2 - 5’ ACACUGGAACAGCGGAUGCTT 3’ 
 
 c-Myc   
 #1 - 5' GGAACGAGCUAAAACGGAGTT 3’ 
 #2 - 5’ CUCCGUUUUAGCUCGUUCCT 3’ 
 
3.1.11 Expression vectors 
 
Vectors    Backbone               Tags 
wt-NFATc2    pcDNA3.1    HA  
wt-NFATc1   pREP4      - 
NFATc2 promoter   pcDNA3.1    Luc 
NFATc1 promoter  pREP4      Luc 
c-Myc-I    pBV-Luc    Luc 
c-Myc-II    pBV-Luc    Luc 
c-Myc-III   pBV-Luc    Luc 
c-Myc-IV   pBV-Luc    Luc 
c-Myc-V    pBV-Luc    Luc 
c-Myc-VI   pBV-Luc    Luc 
c-myc-pGL3-A   pGL3-Enhancer   Luc 
c-myc-pGL3-B   pGL3-Enhancer   Luc 
c-myc-pGL3-C   pGL3-Enhancer   Luc 
c-myc-pGL3-D   pGL3-Enhancer   Luc 
c-myc-pGL3-E   pGL3-Enhancer   Luc 
c-myc-pGL3-F   pGL3-Enhancer   Luc 
c-myc-pGL3-NFATmut  pGL3-Enhancer   Luc 
 
   Materials and Methods 
22 
 
3.1.12 List of antibodies for Western blot analysis 
 
Antibodies    Dilutions  Source 
Mouse anti-mouse NFATc1  1:1,000  Abcam 
Mouse anti-mouse NFATc2  1:500   Santa Cruz 
Mouse anti-mouse Smad3  1:1,000  Abcam 
Mouse anti-mouse Smad2/3  1:500   B.D Biosciences 
Rabbit anti-rabbit pSmad3  1:1,000  Cell Signalling 
Mouse anti-mouse Smad4   1:1,000  B.D Biosciences 
Mouse anti-mouse c-Myc   1:500   Santa Cruz 
Mouse anti-mouse CyclinD1   1:1,000  Cell Signalling 
Mouse anti-mouse CyclinD3   1:1,000  Cell Signalling 
Mouse anti-mouse CdK4  1:1,000  Cell Signalling 
Mouse anti-mouse CdK6   1:1,000  Cell Signalling 
Mouse anti-mouse β-actin   1:10,000  Sigma 
Rabbit anti-mouse Lamin A/C  1:1,000  Santa Cruz 
 
3.1.13 List of antibodies for ChIP analysis 
 
Antibodies    Amount  Source 
Rabbit anti-human NFATc1   4 µg   ImmunoGlobe 
 
Rabbit anti-human NFATc2  4 µg   ImmunoGlobe 
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3.2 SOLUTIONS AND BUFFERS 
 
3.2.1 Mediums and buffer solutions 
 
All chemicals of molecular biology research grade were procured from 
respective manufacturers and all solutions were prepared using pure distilled 
(Milli-Q grade) autoclaved water. Wherever necessary, solutions were sterile 
filtered or autoclaved.  
 
3.2.1.1 Cell biological 
 
PBS (Phosphate buffered saline) 
8 g  NaCl 
 0.2 g  KCl 
1.44 g  Na2HPO4 
0.24 g  KH2PO4 
Dissolve in 800 ml dH2O, adjust pH to 7.4 with HCL 
Volume adjust to 1 L, autoclave and stored at RT 
 
Reagents      Source 
DMEM medium     Invitrogen 
L-Glutamin (0.07%)     GIBCO 
Na-Pyruvat (1 mM)     GIBCO 
β-Mercaptoethanol (0.05 mM)   GIBCO 
MEM (non-essential amino acids) (1%)  GIBCO 
 Penicillin (100 U/ml)     Grunthal 
 Streptomycin (100 U/ml)    Fatol 
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Composition of SDS-Polyacrylamide gels:  
 
Resolving Gel 
Component volumes (ml) per 10 ml gel mix for 10% to 15% 
H2O 3.3 - 4.6 ml 
30% acrylamide mix 2.7 ml - 4.0 ml 
1.5 M Tris (pH 8.8) 2.5 ml 
10% SDS 0.1 ml  
10% ammonium persulfate 0.1 ml  
TEMED 0.004 ml 
 
Stacking Gel: 
Component volumes (ml) per 3 ml gel mix for 10% to 15% 
H2O 2.1 ml 
30% acrylamide mix 0.5 ml 
1.0 M Tris (pH 6.8) 0.38 ml 
10% SDS 0.03 ml 
10% ammonium persulfate 0.03 ml 
TEMED 0.003 ml 
 
Protein Loading Buffer (1X SDS gel loading buffer) 
50 mM Tris-Cl (pH 6.8) 
100 mM Dithiothreitol 
2% SDS 
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0.1% Bromophenol blue 
10% Glycerol 
 
Gel Running Buffer: (10X) 
144.13 g Glycine 
30.3 g Tris 
100 ml 10% SDS 
Volume adjusted to 1 L with dH2O 
 
Protein transfer buffer: (10X) 
145 g Glycine 
29 g Tris 
volume adjusted to 1 L with dH2O 
 
Blocking Solution 
5% (w/v) nonfat dried milk in TBS/0.1% Tween 
 
Agarose gel electrophoresis 
TBE buffer (1x): 
10.8 g  Tris 
5.5 g  Boric acid 
0.37 g  EDTA 
add  1 L H2O 
 
DNA Loading Buffer: 
0.25% Bromophenol blue 
0.25% Xylene Cyanol FF 
30% Glycerol in water 
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1% Agarose Gel:  
1.5 g Agarose 
150 ml 1x TBE buffer 
boil and add 4 µl Ethidium bromide (10 mg/ml) 
 
Cell extract preparation 
Whole cell extract (WCE) buffer: 
5mM Tris HCL, pH7.4 
150 mM NaCl 
1 mM EDTA 
1% Triton X-100 
Protease inhibitor cocktail was added immediately before use.  
 
Cellular Fractionation Buffer 
For cytoplasmic protein: 
10 mM Hepes, pH 7.9 
10 mM  KCl 
0.1 mM EDTA 
0.1 mM EGTA 
0.1 M DTT 
 
For nuclear protein: 
20 mM Hepes, pH 7.9 
0.4 M  NaCl 
1 mM EDTA 
1 mM EGTA 
0.1 M DTT 
Protease inhibitor cocktail was added immediately before use 
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Cell lysis buffer for IP: 
5 mM Tris HCL, pH7.4 
150 mM NaCl 
1 mM EDTA 
1% Triton X-100 
(10X) wash buffer for IP 
0.5 M Tris HCL, pH 7.4, 1.5 M NaCl 
Protease inhibitor cocktail was added immediately before use 
 
3.2.1.3 Reagents for ChIP analysis 
 
Lysis buffer I (hypotonic lysis buffer): 
5 mM PIPES, pH 8 
85 mM KCl 
0.5% NP40 
Protease inhibitor cocktail was added immediately before use. 
 
Lysis buffer II: 
10 mM Tris-HCL, pH 7.4 
150 mM NaCl 
1% (v/v) NP40 
1 mM EDTA 
1% sodium deoxycholate (fume hood) 
0.1% SDS 
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Wash buffer I (mixed micelle buffer): 
20 mM Tris, pH 8.1 
150 mM NaCl 
2 mM EDTA 
0.1% SDS 
0.1% Triton X-100 
 
Wash buffer II (buffer 500): 
20 mM Tris, pH 8.1 
500 mM NaCl 
2mM EDTA 
0.1% SDS 
0.1% Triton X-100 
 
Wash buffer III (LiCl detergent buffer): 
10 mM Tris, pH 8.1 
250 mM LiCl 
1% NP40 




20mM Tris, pH 8.0 
1mM EDTA, pH 8.0 
 
Elution buffer: 
500µl 20% SDS 
1ml  1M Na2CO3 
H2O upto 10 ml 
Always prepare fresh elution buffer 
 
 





3.3.1 Preparation of competent cells (CaCl2 method) 
 
Inoculate an overnight pre-culture from a single colony on a prestreaked 
plate (from glycerol stock) in 2 ml LB or 2X TY media by incubation at 37°C 
and shaking to aerate. On the second day, inoculate 1 ml of the pre-culture in 
100 ml fresh media and grow the culture at 37°C until OD at wavelength 600 
nm. Cool down the culture on ice for at least 15 min. The following 
procedures should be carried out at 4°C in pre-cooled sterile tubes. Harvest 
the cells in a centrifuge at 5000 rpm for 5 min, and discard the supernatant. 
Resuspend the bacterial pellets thoroughly in a small volume of ice-cold 100 
mM CaCl2. Dilute the suspension with the CaCl2 solution to a final volume of 
30-40 ml, and leave on ice for 25 min with occasional shaking. Spin down the 
cells as before, discard the supernatant carefully and resuspend the pellet in 
5 ml glycerol/CaCl2. The suspension can be aliquoted in 100 to 400 μl and 
stored at –80°C. The transformation efficiency of the bacteria prepared by 
this method should reach at least 5X10
6
cfu/mkg of plasmid DNA.  
 
3.3.2 Transformation of competent bacteria 
 
Thaw the competent bacteria on ice. Add ligated DNA or purified plasmid-
DNA to 100 μl suspension of competent cells in a cold 1.5 ml microfuge tube. 
Mix carefully and keep on ice for 30 min. Heat-shock the bacteria at 42°C for 
40 sec, chill on ice for 2 min and add 500 µl antibiotic-free LB medium, and 
shake at 37°C for 1 hr. Selection of transformed bacteria is done by plating 
aliquots of the bacterial suspension on agar plates containing respective 
antibiotics. A single colony can then be picked, expanded in LB medium and 
used for DNA preparation.  
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3.3.3 Bacterial manipulation 
 
Plasmid transformed bacteria are selected on LB plates with the appropriate 
antibiotic for 24 hr. For overnight mini cultures, single colonies are picked and 
inoculated into LB medium with antibiotic and shaken overnight at 37°C. This 
pre-culture is then used for preparing frozen glycerol cultures, plasmid DNA 
or protein purification. For storage of bacteria, a glycerol stock culture is 
prepared by growing bacteria to an OD of 0.8 at a wavelength of 600 nm in 
culture medium. 500 μl bacterial cultures has to be added to 500 μl 80% 
glycerol and then mixed thoroughly in a small 1.5 ml tube. This stock solution 
is subsequently frozen at –80°C. To inoculate an overnight culture again, 
bacteria are taken and held at room temperature (RT) until surface is thawed. 
A small amount of cells is picked, mixed into 2-5 ml culture medium and left 
to grow for 12-16 hr at 37°C in a bacterial culture shaker.  
 






c-myc Del. VI Amp 










NFATc2 wt Amp 
NFATc1 wt Amp 
Smad3 wt Amp 
 
3.4 EXPERIMENTAL PROCEDURES 
 
3.4.1 Cells and transfection 
 
Panc-1 (ATCC, CRL-1469), 8988t (DSMZ, ACC 162) and HaCaT (CLS #300493) 
cells were maintained in DMEM (Invitrogen Life Technologies, Karlsruhe, 
Germany) supplemented with 10% FCS. Expression and reporter promoter 
plasmids were transfected at 70% cell confluence using TransFast (Promega, 
Madison, WI). Short interfering RNA (siRNA) was transfected using 
TransmessengerTM reagent (Qiagen, Hilden, Germany) or SiLentfect (from 
bio-Rad), according to the manufacturer’s instructions and cells were treated 
with 10 ng/ml TGF-β and harvested at indicated time points. 
 
3.2.4 Preparation of whole protein extract from mammalian 
cells  
 
Cells were washed with ice cold PBS and then scraped in whole cell extract 
buffer. Then transferred them into 1.5 ml tubes. Kept on ice for 30 min to 1 h. 
Cells were disrupted by two times freezing and thawing on dry ice or passing 
the cell suspension through 26 gauge needle 10 times and incubated for 
further 10 min. The cell suspension was centrifuged at 15,000 rpm for 30 min 
at 4°C and supernatant was saved as whole cell extract in another 1.5 ml 
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tube, which was stored for future use at -20°C. The protein concentration of 
the supernatant was determined by Bio-Rad protein assay.  
 
3.2.5 Preparation of nuclear and cytoplasmic protein extracts 
from mammalian cells  
 
Cells were washed and scraped in cold PBS. Transferred them into 1.5 ml tube 
and centrifuge at 1500 rpm for 5 min at 4°C to remove the supernatant. The 
pellet was resuspended in 200 μl to 1 ml of extraction buffer A (100 μl per 
1x10
7
 cells) and incubated for 20-30 min at 4°C or on ice. Extraction buffer A 
is a low salt buffer (indicates that DTT and PMSF were added to buffer A), 
which allowed the cells to swell. To destroy the swollen cells, the solution was 
passed 10 times through 1 ml syringe with 26 gauge needle and centrifuged 
at 3,600 rpm for 20 min at 4°C. The supernatant contained cytosolic fraction 
and the pellet, which appeared transparent, containing nuclear fraction. The 
supernatant was transferred to a fresh 1.5 ml tube and kept on ice. The pellet 
was resuspended with 200 μl extraction buffer C (leupeptin was added in 
addition to DTT and PMSF) by pipetting and vigorously mixing with force, 
followed by vortexing the nuclear extract vigorously for 30 min and incubate 
on ice for 30 min. Now the suspension was centrifuged at 15,000 rpm for 30 
min at 4°C and supernatant containing nuclear proteins was frozen in –20°C. 
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3.2.6 Protein determination  
 
The Bio-Rad protein assay is based on the observation that when Coomassie 
brilliant blue G-250 binds to the protein, the absorbency maximum shifts 
from 450 nm to 595 nm. Equal volumes of cell lysate containing 1-20 μg of 
protein was added to diluted dye reagent and mixed well (1:5 dilution of dye 
reagent concentrate in dH2O). After 5-10 min, the absorption at wavelength 
at 595 nm was measured versus reagent blank (which contains only the lysis 
buffer). 
 
3.2.7 SDS-polyacrylamide gel electrophoresis 
 
SDS-polyacrylamide gels were prepared in 8 cm x 10 cm x 1.5 mm mini gel 
format according to the standard Laemmli method. Separating or lower gel 
mix was prepared according to the volume required, poured in the gel 
apparatus, overlaid gently with 0.1% SDS and before the separating gel 
polymerized, immediately poured the stacking gel, the comb was inserted 
and allowed to polymerize at RT for 1 h to 2 h. Requisite concentrations of 
protein samples were mixed with 4x Laemmli buffer and denatured by 
heating at 95°C for 5 min, loaded in the wells, (one well was loaded with 
protein marker) of polymerized gel and electrophoresed at constant current 
initially at 120 V and when the marker start separating current increased up 
to 160 V per gel in 1X SDS-PAGE running buffer. 
 
3.2.8 Western blotting 
 
SDS-PAGE gel was electrotransferred onto nitrocellulose membrane at 300- 
400 mA for 90 min at 4°C. The air dried membrane was incubated in a 
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blocking solution (5% fat free milk in 1X TBS-Tween) for 1 h at RT. Membrane 
was directly incubated in primary antibodies against cyclinD1, CDK4, CDK6, 
GSK3β, HA, Lamin a/c, HDM2, p53, NFATc2, Ubiquitin and β-actin antibodies 
over night at 4°C. After incubation, the membrane was washed in 1X TBS-
Tween for 3 X 10 min each. Now membrane was incubated in secondary 
antibodies conjugated with peroxidase against mouse or rabbit antibody for 
1-2 h at room temperature and washed in 1 X TBS-Tween for 3 X 10 min each. 
Proteins were visualized and developed with ECL developing solution 
according to the manufacturer's instructions. 
    
3.2.9 siRNA transfection 
 
Small interfering RNA (siRNA) was transfected using the Transmessenger
TM
 
reagent (Qiagen) or SiLentfect (Bio-Rad) according to the manufacturer´s 
instructions. The specific siRNAs were purchased from Ambion Applied 
Biosystems (Austin, TX) with the following sequences: NFATc1 #2 5’ 
GGACUCCAAGGUCAUUUUCTT 3’; NFATc2 #3 5’ CCAUUAAACAGGAGCAGAATT 3’; #2 5’ 
GCUGAUGAGCGGAUCCUUATT 3’; Smad3 #1 5’ GCAUCCGCUGUUCCAGUGGUTT 3’; #2 5’ 
ACACUGGAACAGCGGAUGCTT 3’; c-Myc #1 5' GGAACGAGCUAAAACGGAGTT 3’; #2 5 
’CUCCGUUUUAGCUCGUUCCT 3’. As a negative control, the silencer negative-control 
from Ambion was used. 
 
3.2.10 Proliferation assay and cell cycle analysis 
 
Panc-1, 8988t or HaCaT cells were seeded in 12-well plates and cultured in 
medium containing 10% FCS until attachment. After attachment, cells were 
starved for 24 hr in serum free medium and either transfected with siRNA or 
treated with TGF-β (10 ng/µl) for indicated time periods. [
3
H] thymidine 
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(0.5uCi/well) was added during the last 6 hr of incubation. Incorporated [
3
H] 
thymidine was quantified as described previously. For statistical analysis, 
Students t-test was used and p < 0.05 was considered significant. Cell cycle 
analysis was performed by flow cytometry. Cells were treated with 10 ng/µl 
TGF-β for 0 hr, 18 hr, 24 hr and 48 hr, then trypsinized, washed with PBS and 
fixed in 70% ethanol. After washing with PBS, cells were incubated with 20 
µg/ml RNase, DNase-free water with 50 µg/ml propidium iodide for 3 hr at RT 
under light protection. The DNA content of 10
6
 cells was analyzed on a 
Becton Dickinson FACS Calibur flow cytometer (San Jose, CA). The fractions of 
cells in the G0/G1, S and G2/M phases were calculated using Cell Quest 




RNA was extracted using the RNeasy Mini Kit (Qiagen) and first-strand cDNA 
was synthesized from 1 µg total RNA using random primers and the 
Omniscriptfirst-strand synthesis kit (Qiagen) according to the manufacturer’s 
instructions. The qRT-PCR was performed using a 7500 Fast-Real-Time-PCR-
System from Applied Biosystems (Foster City, MA). Specific primer pairs were 
designed with the PrimerExpress 3.0 (Applied Biosystems, Wellesley, MA) as 
followed: cyclophilin A for 5’ CACCGTGTTCTTCGACATCA 3’, rev 5’ AGCA 
TTTGCCATGGACAAGAT 3’; c-Myc for 5’ GCTCCTGGCAAAAGGTCAGA 3’, rev 5’ 
CAGTGGGCTGTGAGGAGGTT 3’. 
 
3.2.12 DNA pull-down 
 
Panc1 and 8988t cells were treated with TGF-β (10 ng/µl) for the indicated 
time periods. In total, 100 µg of nuclear protein per sample were incubated 
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for 3 hr with 1 µg of biotinylated double-stranded oligonucleotides containing 
the GGAAA consensus NFAT-binding sequence of the wild-type TIE element 
(wt TIE), the wild type TIE element (TIE-wt, _92 to _63 relative to the c-myc 
P2 transcription start site; 50- 5’ TTCTCAGAGGCT TGGCGGGAAAAAGAACGG 
3’ -30 and 5’ CCGTTCTTTTTCCCGCCAAGCCTCTGAGAA 3’) or the NFAT mutant 
TIE sequence (TIE-M1; 50- 5’ TTCTCAGAGGCTTGGCGGGCCCAAGAACGG 3’-30 
and 5’ CCGTTCTTGGGCCCGCCAAGCCTCTGAGAA 3’). DNA–protein complexes 
were collected by precipitation with streptavidin–agarose beads (Sigma-
Aldrich) for 1 hr, washed twice with lysis buffer including proteinase and 
phosphatase inhibitors and subjected to SDS-PAGE analysis.  
  
3.2.13 Chromatin Immunoprecipitation Analysis (ChIP) 
 
ChIP assays were performed in Panc-1 and 8988t cells treated with TGF-β  (10 
ng/µl) for the indicated time periods. Cells were cross-linked with 1% 
formaldehyde for 10 min at 37°C, harvested in SDS lysis buffer (Upstate 
Biotechnology), and DNA was shredded to fragments of 500 bp by 
sonification. Antibodies against NFATc2, NFATc1 or Smad3 were added to 
each aliquot of pre-cleared chromatin and incubated over night. Protein G 
agarose beads were added and incubated for 1.5 hr at 4°C. After reversing 
the cross-links, DNA was isolated and used for PCR reactions. Specific primer 
pairs were designed with the Primer Express 3.0 as followed: c-Myc primer 4 
for.- 5’ AGGGCTTCTCAGAGGCTTG 3’,  rev.- 5’ TGCCTCTCGCTGGAATTACT 3’ 
and c-Myc primer 17 for- 5’ GAGGGATCGCGCTGAGTAT 3’ rev - 5’ 
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3.2.14 Luciferase Reporter Assays 
 
For luciferase reporter gene assays, 10
6 
cells were seeded into 12-well tissue 
culture dishes and transfected after 24 hr with the indicated constructs. 
Treatment with TGF-β (10 ng/µl) as maintained 24 hr after transfection for 
the indicated time periods. Luciferase assays were performed with a Lumat 
LB 9501 luminometer (Berthold Technologies) and the Dual-Luciferase
®
-
Reporter Assay System (Promega). Firefly luciferase values were normalized 
to Renilla luciferase activity and were either expressed as relative luciferase 
activity (RLA) or as mean ‘fold induction’ with respect to empty vector 
control. Mean values are displayed +/-standard deviations. 
 
3.2.15 Statistical analysis 
 
Each experiment was reproduced at least three times. Values are expressed 
as the mean ± SD of triplicate measurements unless otherwise stated. 
Student’s paired t-test was used to analyze differences between the sample 
of interest and its control. Time courses and dose responses were compared 
by multiple measurements ANOVA and corrected by student-Newman–Keul’s 
test for differences between groups. A p value of less than 0.05 was 











4.1 TGF-ΒETA PROMOTES CELL PROLIFERATION VIA 
G1/S PHASE PROGRESSION IN CANCER CELLS  
 
TGF-β signalling is known for its functional diversity in malignant and non-
malignant cells. In order to test the effect of TGF-β on cancer cell growth, we 
performed proliferation assays in the pancreatic cancer cell lines 8988t and Panc-
1. Therefore, serum starved cells were stimulated with TGF-β 10 ng/ml for 
indicated time periods. Cell proliferation was assessed by incorporation of [
3
H] 
thymidine. TGF-β stimulation caused a significant increase in cell proliferation of 
Panc-1 and 8988t cells. Induction of cell proliferation occurred in a time 
dependent manner and became significant after 48hr. This effect was 
independent of Smad4 signalling (Figure 1) because one of the tested cell line has 
mutations in the Smad4 gene (8988t (Elsässer et al., 1992)). As TGF-β is known for 
its growth inhibitory effects in non-malignant epithelial cells, we tested HaCaT 
keratinocytes, which are sufficiently growth inhibited by TGF-β (Figure 2). 
 
 
Figure 1) TGF-β promotes cell proliferation. Proliferation assays demonstrated the increased 




or treated with 10ng/μl TGF-β over the indicated time periods, 0 hr, 24 hr and 48 hr. Cell 
proliferation was assessed by incorporation of [
3
H] thymidine in all the cells. Data are 
representative of triplicate experiments and are displayed as bars ± SD.  
 
 
Figure 2) TGF-β inhibits cell proliferation in keratinocytes. The influence of TGF-β 10 ng/ml on 
growth inhibition in HaCaT cells was assessed by incorporation of [
3
H] thymidine. Cells were kept in 
serum free medium with TGF-β (blue bars) or without TGF-β  (red bars) for 24 and 48 hr. Data are 
representative of triplicate experiments and are displayed as bars ± SD.  
 
Flow cytometry analysis revealed that the growth promoting effect of TGF-β in 
8988t and Panc-1 cells resulted from increased cell cycle progression, as evidenced 
by the shift of cells from G1 to S and G2 phases (Figure 3). Moreover, cell cycle 
progression in growth promoted cells was reflected by increased expression of D-
type cyclins (cyclin D1 and cyclin D3) and their corresponding kinases CdK4 and 
CdK6 (Figure 4), which are known to be required for cell proliferation. TGF-β 
stimulation induced the expression of cyclin D1 and cyclin D3 and their related 







Figure 3) TGF-β induces G1/S phase transition in pancreatic cancer cells. Flow cytometry analysis 
was performed after propidium iodide (PI) staining in response to 10 ng/μl TGF-β treatment for 24 
hr and 48 hr. Cell cycle stages are illustrated in different colors: G2 (yellow), S (brown), and G1 
(green). Bars indicate mean values ± SD of three independent experiments.  
 
 
Figure 4) TGF-β induces G1/S phase transition via D-type cyclins. Western blot analysis examined 
the effect of TGF-β on the expression of cell cycle regulatory genes in growth promoted cell lines. 
Panc-1 and 8988t cells were incubated for 0 hr, 24 hr, and 48 hr in the presence (+) or absence (-) 
of TGF-β as indicated. Total cell lysates were prepared and then visualized by immunoblotting by 
using antibodies for phosphorylation of Smad3 at C-terminal, cyclinD1, cyclinD3, CdK4 and CdK6. 









4.2 c-MYC IS REQUIRED FOR TGF-ΒETA INDUCED CANCER 
CELL PROLIFERATION  
 
To explore the TGF- β induced cell proliferation in more detail, we examined the c-
Myc expression in cancer cells after TGF-β stimulation. C-Myc acts as 
transcriptional activator of growth and proliferation in response to growth stimuli. 
Interestingly, we found that TGF-β stimulation induced the c-Myc expression on 
both mRNA (Figure 5A) and protein level (Figure 5B) in growth promoted Panc-1 
and 8988t cells. As expected and known before, TGF-β reduced the c-Myc 
expression on both mRNA (Figure 6A) and protein level (Figure 6B) in growth 
inhibited HaCaT cells. 
 
 
Figure 5) TGF-β induces c-Myc expression on mRNA and protein level in cancer cells. (A) TGF-β 
mediated induction of c-Myc mRNA expression was analyzed by RT-PCR in Panc-1 and 8988t cells. 
Serum starved cells were left untreated or treated with 10 ng/μl TGF-β for 24 hr before RNA 
extraction. mRNA expression levels were calculated relative to basal mRNA expression, which were 




confirmed on protein level in Panc-1 and 8988t cells after stimulation with 10 ng/μl TGF-β for 18 hr 
and 24 hr. Total cell lysates were prepared and analyzed for c-Myc protein content by using anti-c-
Myc antibodies. Protein loading was controlled using β-actin antibodies. 
 
 
Figure 6) TGF-β down regulates c-Myc expression on mRNA and protein level in HaCaT cells. (A) 
Real time-PCR analysis to demonstrate c-Myc mRNA and protein expression in HaCaT cells upon 
TGF-β stimulation. Serum starved cells were left untreated or treated with 10 ng/μl TGF-β  before 
RNA extraction. mRNA expression levels were calculated relative to basal mRNA expression levels 
and expressed as -fold induction. (B) Total cell lysates were extracted from the cells treated and 
untreated with 10 ng/μl TGF-β  over  0 hr, 18 hr and 24 hr. Western blot analysis was performed by 
using c-Myc antibodies. Protein loading was controlled using β-actin antibody. 
 
The increased c-Myc expression after stimulation with TGF-β was caused by 
enhanced activity of the c-Myc promoter. Stimulation with TGF-β or transfection 
of a constitutive active TGF-β type-I receptor (TβRI) induced a 2 to 4-fold increase 
in c-Myc promoter activity, as revealed by reporter gene assays using a luciferase 
reporter construct that encompasses a 2.8 kb region of the human c-Myc 






Figure 7) Transactivation of c-Myc promoter by TGF-β. Reporter gene assays illustrating the effect 
of TGF-β on human c-Myc promoter activity in 8988t and Panc-1 cells. Cells were transfected with 
a luciferase reporter gene construct containing the wild-type c-Myc promoter sequence along with 
Renilla luciferase plasmid and treated with 10 ng/μl TGF-β for 18 hr and 24 hr, in Panc-1 cells. 
8988t cells were transfected with TβRI along with wild type c-Myc promoter. Firefly luciferase 
reporter gene activities were measured, normalized to TK-Renilla luciferase and expressed as mean 
-fold induction compared with untreated controls. Mean values were calculated from four 
independent experiments and are expressed as -fold induction.  
 
To investigate the functional role of the TGF-β mediated c-Myc induction in cancer 
cells, we transientely knocked down c-Myc expression in Panc-1 cells by RNAi 
technology and examined the effect of TGF-β on cell growth in the absence of c-
Myc. Dramatic reduction of cell proliferation was seen in proliferation assays after 
c-Myc knockdown, as compared to the cells transfected with control siRNA (Figure 
8 – A and B). Interestingly, stimulation with TGF-β showed no effect on cell 
proliferation after knock-down of c-Myc in the tested cancer cells. Together, these 
results identified a novel mechanism of TGF-β in induction of cell proliferation by 






Figure 8) Silencing of c-Myc restores TGF-β antiproliferative behaviour. Reduction of c-Myc was 
confirmed on protein levels in Panc-1 cells after stimulation with TGF-β for 48 hr. (A) The relevance 
of c-Myc induction for TGF-β  induced cell proliferation was assessed by [
3
H] thymidine 
incorporation assays upon c-Myc silencing. Panc-1 cells were transfected with either control siRNA 
or siRNA against c-Myc in serum free medium. Starved cells were then incubated in serum free 
medium with or without 10 ng/μl TGF-β for 48 hr. Cell proliferation was assessed by incorporation 
of [
3
H] thymidine in control and c-Myc knock down cells with and without TGF-β. Bars indicate 
mean values ± SD of three independent experiments. (B) Total cell lysate extraction of protein 
showed successful c-Myc knockdown as demonstrated by immunoblotting. Protein loading was 
controlled using anti-β-actin antibody. (Note that c-Myc depletion rendered cells refractory to TGF-
β growth stimulation.) 
 
4.3 NFAT TRANSCRIPTION FACTORS ARE ESSENTIAL FOR 
c-MYC INDUCTION BY TGF-ΒETA IN CANCER CELLS 
 
To identify regulatory elements within the c-Myc promoter in response to 
stimulation with TGF-β, we used deletion constructs of the human c-Myc 
promoter shown in figure 9. Panc-1 cells were transfected with the indicated c-
Myc promoter constructs (I-VI) along with TβRI. Interestingly, sequential deletion 
of the c-Myc promoter unveiled sustained TGF-β responsiveness up to the 




element (c-Myc del VI), however, impaired TGF-β inducibility of the c-Myc 
promoter in pancreatic cancer cells (Figure 9).  
 
 
Figure 9) TGF-β increases the c-Myc expression by enhanced promoter activity. Panc-1 cells were 
co-transfected with either the full-length c-Myc promoter construct (c-Myc del I, -2446 to +334) or 
the indicated deletions constructs (c-Myc del II-VI) along with TβRI, or a control vector along with 
Renilla luciferase consturct. Firefly luciferase reporter gene activities were measured, normalized 
by TK Renilla luciferase and expressed as RLA (relative luciferase activities). Mean values were 
calculated from three independent experiments and are expressed as fold induction. 
 
Similar to the results obtained with the 2.8 kb wild-type c-Myc promoter 
construct, TGF-β signalling either by transfection of TβRI plasmid or stimulation by 
TGF-β, increased the luciferase activity of the c-Myc promoter construct 






Figure 10) TGF-β increased c-myc expression is dependent on the TIE element within the c-myc 
promoter. 8988t and Panc-1 cells were transfected with the c-Myc/TIE reporter gene construct (-
84 to -63) and TGF-β signalling was initiated by either treatment with 10ng/μl TGF-β or co-
transfection of TβRI along with Renilla luciferase plasmids. Firefly luciferase reporter gene activities 
were measured, normalized by TK Renilla luciferase and expressed as fold induction of luciferase 
activity. Reporter gene activities were expressed as mean fold induction compared to untreated 
control which was arbitrarily set to 1. Mean values were calculated from three independent 
experiments and are shown as mean ± standard deviation.  
 
To elicit the functional relevance of the TTGG core sequence of the TIE element as 
well as the E2F and Smad binding sites within the TIE element of the c-Myc 
promoter in the context of the transactivation by TGF-β, we performed luciferase 
experiments using a c-Myc promoter construct containing a wild-type TIE element 
or a TIE element harboring several point mutants as demonstrated in figure 11. 
TGF-β inducibility of the c-Myc/TIE construct was accelerated upon mutational 
disruption of either the core sequence or the overlapping Smad/E2F interacting 
sequences, indicating that the repressor elements are potentially operative in 
proliferating cells (Figure 11, bars B-E). However, site directed mutagenesis of a 
neighboring NFAT binding motif (GGAAA, located between -75 and –71 relative to 
the P2 transcription initiation site) completely abolished TGF-β responsiveness of 






Figure 11) TGF-β increases c-Myc expression by enhanced promoter activity and is dependent on 
the NFAT consensus site within the TIE element. Schematic representation of the human c-myc 
TIE element including previously identified binding sites for SMADs and E2F4. The GGAAA NFAT-
consensus sequence is also indicated. The table displayed the individual or combined mutations 
targeting these transcription factor binding sites as used for luciferase reporter gene assays (TIE 
mutants A-F). 8988t and Panc-1 cells were transfected with the indicated wild-type c-Myc/TIE 
construct (bar A in blue) or mutant c-Myc/TIE reporter constructs (bars B-F), along with TβRI or 
wild-type NFATc1/NFATc2 expression plasmids along with Renilla luciferase plasmid. Reporter gene 
activities were expressed as RLA (relative luciferase activities). Mean values were calculated from 






These findings suggested a role of NFAT factors in TGF-β induced c-Myc promoter 
activation in proliferating cells. To test the ability of NFAT to bind to the detected 
consensus sequence within the TIE-element, we performed DNA pulldown assays 
using a biotinylated double stranded oligonucleotides containing a wild-type NFAT 
binding sequence (c-Myc/TIEwt) and a mutated NFAT binding sequence (c-
Myc/TIE-NFAT mut). Using the c-Myc/TIEwt oligonucleotides, we could detect 
NFAT bound to the DNA following stimulation with TGF-β in Panc-1 cells. But we 
could not detect NFAT binding to the c-Myc/TIE oligonucleotides following TGF- β 
stimulation when the NFAT consensus site was mutated (Figure 12). To confirm 
DNA binding of NFAT to its consensus sequence within the TIE-element after 
stimulation with TGF-β in an in vivo situation, we performed chromatin 
immunoprecipitation studies (ChIP) in Panc-1 cells using anti-NFATc1 antibodies. 
Rapid induction of NFAT binding to the full-length c-Myc promoter was observed 
after 3h of TGF-β stimulation (Figure 13). Additionally, a nearly 3-fold increase of 
NFAT binding to a 60 base pair fragment of the c-Myc promoter containing the TIE 
element (Figure 14) was detectable after stimulation with TGF-β β. Together, 
these results show a binding of NFAT to the TIE element within the c-Myc 
promoter following stimulation with TGF- β. 
 
 
Figure 12) NFAT binds on c-Myc promoter within TIE element in the DNA pull down assay. DNA 
pulldown assays performed by using double-stranded oligonucleotides of wild-type and mutant TIE 
with disruption of the NFAT binding site. Panc-1 cells were serum starved and then treated with 10 
ng/μl TGF-β  for 0 hr, 18 hr, 24 hr and 48 hr. Nuclear extracts were prepared and incubated with 




streptavidin–agarose beads and NFAT binding was analyzed by western blotting using NFATc1 
antibodies. 
 
Figure 13) NFAT directly binds on c-Myc promoter. Chromatin immunoprecipitations were 
performed with specific NFATc1 antibodies in Panc-1 cells and in vivo binding to the c-Myc 
promoter was determined by semiquantitative PCR using primers specific for the full length c-Myc 
promoter region harboring the TIE. 
 
 
Figure 14) NFAT directly binds on c-Myc promoter. Chromatin immunoprecipitations were 
performed with specific NFATc1 antibodies in Panc-1 cells and in vivo binding to the c-Myc 




promoter region harboring only the TIE. Mean values were calculated from three independent 
experiments which were performed in triplicates. Bars indicate mean values ± standard deviation. 
 
 
4.4 TGF-ΒETA MODULATES NFAT ACTIVITY IN A SMAD-
INDEPENDENT MANNER  
 
Recent studies have demonstrated that NFAT proteins fulfill oncogenic functions 
and control critical mechanisms in proliferating cells during carcinogenesis 
(Buchholz et al., 2006; Medyouf & Ghysdael, 2008; Robbs et al., 2008). A basal 
expression of either NFATc1 or NFATc2 is detectable in both cell lines, however, 
none of the cell lines revealed co-expression of both transcriptional regulators. 
NFATc1 expression was detected in Panc-1 cells, whereas NFATc2 was found in 
8988t (Figure 15). Following stimulation with TGF-β, the basal expression of 
NFATc1 and NFATc2 is strongly increased as shown in figure 15. Total cell lysates 
prepared from TGF-β treated cell lines and subjected to immunoblot analysis 
showed also an increased expression of Smad 3, which was more phosphorylated 
after TGF-β treatment showing an activation of the classical Smad signalling 
cascade in our cells. An expression of Smad4, which is increased after TGF-β 
stimulation, is only detectable in Panc-1 cells (Figure 15) because 8988t cells 






Figure 15) TGF-β induced expression of NFATc1/c2 in cancer cells. Total cell lysate extracts were 
prepared for western blot analysis to show time-dependent TGF-β mediated induction of NFAT 
factors in Panc-1 and 8988t cells. Cells were serum starved and then treated with 10 ng/μl TGF-β  
for the indicated time periods 0 hr, 18 hr, 24 hr, and 48 hr. Increased phosphorylation of Smad3 
indicates successful treatment of TGF-β. Protein loading was controlled using β-actin antibodies. 
  
More importantly, TGF-β treatment strongly induced the NFAT expression through 
promoter transactivation. Depending on the cell type and the duration of 
stimulation, TGF-β caused a 3 to 5 fold induction of the human NFATc1 or NFATc2 
promoter as demonstrated in figure 21. These results suggest that TGF- β is able to 




Figure 16) TGF-β induced the NFAT promoter transactivation. Reporter gene assays were 
performed in Panc-1 and 8988t cells following transfection of the human NFATc1 and NFATc2 
promoters and treatment with 10 ng/μl TGF-β for 0 hr, 18 hr and 24 hr, respectively. Firefly 
luciferase reporter gene activities of the NFAT promoters were normalized to Renilla luciferase 
activity and expressed as RLA. Bars indicate mean values ± SD of three independent experiments 
performed in triplicates. Note that both NFAT promoters are induced by TGF-β treatment. 
 
All studied cells, independent of the Smad4 expression status, respond to TGF-β 




enhanced expression of NFAT proteins. To test whether this enhancement of NFAT 
promoter activity is due to the expression of Smads, we performed luciferase 
reporter assays in both pancreatic cancer cell lines using NFATc1 and NFATc2 
promoter construct together with the overexpression of Smad3 and Smad4. 
Neither individual transfection of Smad3 nor Smad4 enhanced the level of NFAT 
promoter activity in growth promoted cells (Figure 17), suggesting a Smad 
independent mechanism of NFAT induction by TGF-β. 
 
 
Figure 17) Smad3 and Smad4 can not transactivate the NFAT promoters. Reporter gene assay to 
define NFATc2 and NFATc1 promoter regulation by Smad3 and Smad4. 8988t and Panc-1 cells were 
transfected with the human NFATc2 and NFATc1 promoters respectively, along with either TβRI or 
Smads. Luciferase measured after 24 hr of transfection. Firefly luciferase reporter gene activities of 
the NFAT promoters were normalized to Renilla luciferase activity and expressed as RLA. Note that 
TGF-β induced NFAT promoters were not responsive to Smads. Fold induction compared to 
untreated control which was arbitrarily set to 1. Bars indicate mean values ± SD of three 







4.5 CALCINEURIN DEPENDENT TGF-ΒETA MEDIATED 
NFAT INDUCTION 
 
As Smad overexpression is not able to increase NFAT promoter activity, we asked 
how TGF-β could induce NFAT expression in cancer cells. One potential signalling 
mechanism that is possibly critical for TGF-β mediated NFAT expression, is the 
activation of calcium-dependent molecules such as calcineurin. It has been shown 
before that calcineurin is required for the induction of several genes in response 
to TGF-β. Interestingly, an increased expression of calcineurin-B was observed in 
8988t cells after TGF-β stimulation in a time dependent manner (Figure 18). 
 
 
Figure 18) TGF-β mediated induction of calcineurin in pancreatic cancer cells. Induction of 
calcineurin-B was confirmed on protein levels in 8988t after stimulation with TGF-β 10 ng/μl for     
0 hr, 18 hr, 24 hr and 48 hr. Total cell lysates were analyzed for calcineurin-B protein content using 
anti-calcineurin-B antibodies. Protein loading was controlled using β-actin antibodies.  
 
NFAT proteins, which are basally phosphorylated and localized within the 
cytoplasm, are substrates of calcineurin (Medyouf et al., 2008). Consistent with 
increased phosphatase activity, the calcineurin substrates NFATc1 and NFATc2 






Figure 19) TGF-β induced calcineurin mediated translocation of NFATc1/c2 in the nucleus. 8988t 
and Panc-1 cells were used, after stimulation of TGF-β 10 ng/μl for 0 hr, 18 hr, 24 hr and 48 hr. 
Nuclear fractions were prepared and subjected to immunoblot analysis using anti-NFATc1, anti-
NFATc2 and anti-Smad3 antibodies. Protein loading was controlled using lamina/c antibodies.  
 
In contrast, application of cyclosporine A (CsA), an inhibitor of the phosphatase 
calcineurin, diminished NFAT induction by TGF-β on both promoter activity and 
mRNA level (Figure 20 and Figure 21), indicating that TGF-β utilize the canonical 
Ca
2+/
calcineurin-signalling pathway to induce a positive NFAT feedback loop in 
proliferating cells. Inhibition of calcineurin prior to the addition of TGF-β revealed 
that calcineurin is required for TGF-β mediated NFAT induction in cancer cell. 
Altogether these results showed that the NFAT promoter activation by TGF-β 
occured in a Smad independent manner but requires an active calcineurin 






Figure 20) TGF-β induced NFATc1/c2 mRNA expression in pancreatic cancer cells by calcium 
influx in the cell. TGF-β mediated induction of NFAT mRNA expression was analyzed by Real Time-
PCR in Panc-1 and 8988t cells. Initially, cells were treated with CsA in serum free medium. Then, 
serum starved cells containing CsA were left untreated or treated with 10 ng/μl TGF-β. RNA 
extraction was prepared 24 hr after TGF-β stimulation. mRNA expression levels were calculated 
relative to basal mRNA expression, which were arbitrarily set to 1 for each experiment, and 
expressed as fold-induction. Bars indicate mean values ± SD of three independent experiments 
performed in triplicates. 
 
 
Figure 21) Cyclosporin rescued the TGF-β mediated transactivation of NFATc1/c2 promoter in 




cyclosporine A (CsA) treatment. Cells were transfected with the human NFATc2 promoter along 
with TβRI and incubated in the presence or absence of CsA to block endogenous calcineurin 
activity. Note that TGF-β induced NFATc2 and NFATc1 promoter activation was antagonized by 
pharmacological inhibition of calcineurin. Bars indicate mean values ± SD of three independent 
experiments performed in triplicates. 
 
4.6 REQUIREMENT OF NFAT FOR TGF-ΒETA MEDIATED  
c-MYC INDUCTION IN CANCER 
 
To identify the importance of NFAT for TGF-β mediated c-Myc induction on 
promoter level, we performed reporter assays in the presence and absence of 
CsA. Therefore, cells were transfected with a c-Myc/TIEwt promoter construct and 
treated with the calcineurin inhibitor CsA. Surprisingly, TGF-β mediated activation 
of c-Myc/TIEwt promoter construct was abolished after treatment with CsA 
(Figure 22). 
 
Figure 22) Cyclosporin rescued the transactivation of c-Myc promoter by TGF-β. Reporter gene 
assays to define c-Myc/TIEwt promoter regulation by cyclosporine A (CsA) treatment. Cells were 




or absence of CsA. Luciferase was measured after 24 hr of transfection. Firefly luciferase reporter 
gene activities of the c-Myc/TIE promoter were normalized to Renilla. Data are represented of 
triplicate experiments and are displayed as bars ±SD.  
 
To investigate the role of NFAT in the context of TGF-β mediated c-Myc induction 
in more detail, we performed NFAT knock down experiments in the presence of 
TGF- β. Twenty-four hours after transfection with control siRNA or NFAT siRNA, 
cells were incubated with TGF-β for up to 48 hours. As shown in figure 23A, knock-
down of NFAT prevents the induction of c-Myc mRNA by TGF-β (Figure 23A). This 
prevention of c-Myc induction was also reflected on protein level, as shown in 
figure 23B. In cells transfected with control siRNA, increased NFAT protein is 
detectable 18 hr after TGF-β treatment while c-Myc enhancement starts after     
24 hr of TGF-β treatment. In case of NFAT knock-down neither an increase of NFAT 
nor of c-Myc was detectable under treatment with TGF- β (Figure 23B). These 
results support the assumption that c-Myc is a transcriptional target of NFAT in 






Figure 23) NFAT expression required for c-Myc induction by TGF-β. (A) Cancer cells were 
transfected with control siRNA or siRNA against NFAT proteins 24 hr post transfection, cells were 
serum starved and then treated with either serum free medium or medium containing 10 ng/μl 
TGF-β. cDNA was prepared and subjected to qRT–PCR to analyze the effect of NFAT knockdown on 
c-Myc mRNA expression in Panc-1 (left) and 8988t (right) cells. Values were calculated relative to 
basal mRNA expression levels in control siRNA transfected cells, which were arbitrarily set to 1 for 
each experiment. Displayed are mean values from three independent experiments ± standard 
deviations. (B) TGF-β treated Panc-1 and 8988t cells transfected with either non-specific control 
siRNA or NFATc1-siRNA and NFATc2-siRNA respectively. Total cell lysate proteins were extracted 
and subjected to immunoblotting with antibodies specific for NFATc1, NFATc2 or c-Myc. Protein 
loading was controlled using β-actin antibodies.  
 
To elucidate the role of the TGF-β/Smad signalling pathway, which is activated in 
response to TGF-β treatment in our pancreatic cancer cells, in the context of c-




after genetic knock-down of Smad3. We can show that knock-down of Smad3 did 
neither prevent TGF-β induced expression of NFATc2 and NFATc1 (Figure 24), nor 
the subsequent induction of c-Myc. The knock-down of Smad also failed to 
prevent activation of the c-Myc promoter following activation of TGF-β signalling 
(Figure 25). Moreover, TGF-β mediated induction of the c-Myc promoter is even 
more enhanced after knock-down of Smad3 (Figure 25). These studies show that 
TGF-β induced and NFAT mediated induction of c-Myc is completely independent 
of Smad signalling. 
 
 
Figure 24) Loss of Smad3 did not affect NFAT and c-Myc expression. Panc-1 and 8988t cells were 
transfected with siRNA against Smad3 or control siRNA, serum starved cells treated in serum free 
medium alone or medium containing 10 ng/μl TGF-β for 0 hr, 18 hr, 24 hr or 48 hr. Total protein 
lysates extracted and immunoblot analysis were performed to determine successful depletion of 
Smad3 and its impact on the expression levels of NFAT and c-Myc in cancer cells. Protein loading 
was controlled using β-actin antibodies. Note that c-Myc expression was not affected following 








Figure 25) Loss of Smad3 did not affect transactivation of c-Myc promoter. Reporter gene assays 
were performed in Panc-1 and 8988t cells following transfection of unspecific siRNA or siRNA 
against Smad3 along with c-Myc/TIE reporter construct along with TβRI plasmid. c-Myc promoter 
activities were expressed as RLA. Firefly luciferase reporter gene activities of the c-Myc/TIE 
promoter were normalized to Renilla. Data are represented of triplicate experiments and are 
displayed as bars ±SD. (Note that deletion of Smad3 did not affect TGF-β inducibility of the c-Myc 
promoter.) 
 
4.7 NFAT ANTAGONIZES THE SMAD3 REPRESSOR 
COMPLEX TO ACTIVATE THE c-MYC PROMOTER 
 
Recent studies in growth-inhibited cells convincingly demonstrated that Smad3 
binding to the TIE element is a prerequisite for c-Myc repression and results in 
growth inhibition (Chen et al., 2002). To learn more about the interplay between 
NFAT and Smad3 on the level of the c-Myc promoter, we performed reporter gene 
assays using a wild type and a mutated TIE-element. As demonstrated in figure 26, 
Smad3 is active on the c-Myc/TIE element in cancer cells and represses the activity 
of a c-Myc promoter construct. Stepwise overexpression of NFATc1 or NFATc2 in 
increasing concentrations however is able to antagonize the effect of Smad3 
mediated repression on c-Myc promoter. In contrast, NFAT failed to antagonize 




cancer cell lines by using a c-Myc promoter construct which harbors a mutated 
NFAT consensus sequence (Figure 26). 
 
 
Figure 26) Competition between Smad3 and NFAT for the c-Myc promoter. Reporter gene assay 
to analyze c-Myc/TIE promoter induction depending on the integrity of the NFAT binding site and 
the amount of NFAT and Smad3. 8988t and Panc-1 cells were transfected with c- Myc/TIE wild-type 
or c-Myc/TIE-mutant that lacks the NFAT binding site and expression plasmid of Smad3 wild type 
along with increasing amounts of NFATc2. c-Myc promoter activities were expressed as mean fold 
induction. Firefly luciferase reporter gene activities of the c-Myc/TIE promoter or c-Myc/TIE 
mutant were normalized to Renilla. Mean value were calculated from three independent 
experiments and are shown as mean ± SD 
 
According to the antagonistic effect of NFAT to the Smad mediated repression of 
the c-Myc promoter, we hypothesized that induction of NFAT by activation of the 
TGF-β pathway interfered with Smad3 promoter binding and displaced this 
transcription factor from the TIE element within the c-Myc promoter. To confirm 
our hypothesis, we performed DNA pulldown experiments by using a wild-type c-
Myc/TIEwt biotinylated double stranded oligonucleotides probe and chromatin 
immunoprecipetation (CHiP) experiments with the precipitation of NFATc2 or 
Smad3 on c-Myc promoter. As known from former experiments, both NFAT and 




15). As shown in figure 27, in vitro (A) and in vivo (B) binding of Smad3 to the c-
Myc/TIE element was found in all cancer cells when they were cultured in the 
absence of TGF-β. However, Smad3 binding to the c-Myc promoter was replaced 
by NFAT from the c-Myc promoter in a time dependent manner following TGF-β 
treatment. Here we have shown that increasing amounts of NFAT overrides 
Smad3 mediated repression of the c-Myc promoter. Together, these experiments 
show an antagonistic interplay between NFAT factors and Smad3 in the TGF-β 
mediated induction of c-Myc in pancreatic cancer cells. 
 
 
Figure 27) NFAT displaces Smad3 from the c-Myc/TIE upon TGF-β. (A) DNA pulldown experiment 
demonstrating inverse binding of NFAT factors and Smad3 on the c-Myc/TIE upon TGF-β. Nuclear 
extracts from Panc-1 (upper panel) and 8988t (lower panel) cells were prepared and incubated 
with the wild-type c-Myc/TIE oligonucleotide sequence. DNA–protein complexes were precipitated 
with streptavidin–agarose beads, and NFAT/Smad3 binding was analyzed by western blotting using 
anti- NFATc1 and anti-Smad3 antibodies, respectively. Note the inverse binding of NFAT factors 
and Smad3 on the c-Myc/TIE sequence upon treatment with TGF-β. (B) Chromatin 
immunoprecipitations were performed in 8988t cells following 10ng/ul TGF-β treatment over 18 hr 
and 24 hr by using specific NFATc2 and Smad3 antibodies. In vivo binding of both transcription 
factrs to the c-Myc promoter was determined by quantitative PCR using primers specific for the c-
myc promoter region harboring the c-Myc/TIE. ChIP assay demonstrates inverse binding of Smad3 





4.8 NFAT MEDIATES THE TGF-ΒETA SWITCH FROM A 
GROWTH SUPPRESSOR TO A PROMOTER OF CELL 
PROLIFERATION 
 
Finally, we investigated the functional relevance of NFAT in TGF-β promoted cell 
cycle progression and tumor cell growth. Similar to the effects of c-Myc knock-
down (demonstrated in Figure 8), depletion of NFAT fully prevented growth 
stimulation by TGF-β in both pancreatic cancer cell lines (Figure 28 –A and B). The 
importance of NFAT in response to TGF-β treatment is demonstrated by 
proliferation assays after knock-down of NFAT. Firstly, basal cell proliferation was 
decreased after NFAT knock-down. But more surprisingly, the TGF-β mediated 
induction of cell proliferation was completely lost after knock-down of NFATc1 or 
c2 in both pancreatic cancer cell lines (Figure 28 A).  
 
 
Figure 28) NFAT proteins mediate the TGF-β switch from growth suppressor to a promoter of cell 






H] thymidine incorporation assay upon NFAT silencing. 8988t and Panc-1 cells were 
transfected with either control siRNA or siRNA against NFATc2 and NFATc1 respectively. Cells were 
starved and incubated in serum free medium with or without 10 ng/μl TGF-β for 48 hr. Bars 
indicate mean values ± SD of three independent experiments. Note that NFAT depletion rendered 
cells refractory to growth stimulation and partially restored TGF-β growth suppressor activities in 
8988t and Panc-1 cells. (B) Total cell lysate protein was extrated from the 8988t and Panc-1 cells, 
using either control siRNA or siRNA against NFATc2 or NFATc1 respectively and then treated with 
TGF-β 10 ng/μl. Successful NFAT knock-down was demonstrated by immunoblotting using specific 
antibodies against NFATc1 and NFATc2 (bottom panel: control siRNA (lane1), control siRNA + TGF- 
β (lane2), siRNA NFAT (lane3) and siRNA NFAT + TGF- β (lane4). Protein loading was controlled by 
using β-actin antibodies. 
 
Moreover, NFAT silencing partially restored the growth inhibitory response of 
cancer cells to TGF-β treatment (Figure 28), as evidenced by down-regulation of 
the cell cycle regulatory genes, especially cyclin D3 and CdK6, and an increased 
halt of cancer cells in G1 upon TGF-β treatment (Figure 29 and Figure 30). Taken 
together, these findings establish NFAT proteins as central mediators in TGF-β 
induced tumor cell growth and strongly support a key role of these transcription 
factors in the molecular switch controlling TGF-β growth response. 
 
 
Figure 29) Silencing of NFAT restores TGF-β induced G1/S phase transition. Flow cytometry 




cells. NFAT knockdown cells (Panc-1 and 8988t) were treated with TGF-β 10ng/ul for 24 hr or 48 hr, 
respectively, and analyzed by propidium iodide staining and flow cytometry. Cell cycle stages are 
illustrated in different colors: G2 (yellow), S (brown), and G1 (green). Loss of NFAT expression 
restored cell cycle inhibition by TGF-β, as evidenced by increased cells in the G1 phase. Bars 




Figure 30) knock down of NFAT prevents induction of Cyclins by TGF-β. Total cell lystes were 
extracted for western blot analysis demonstrating TGF-β regulated cell cycle genes depending on 
the presence or absence of NFAT expression. Cells were transfected with siRNA against NFATc2 or 
unspecific control siRNA, serum starved and subsequently treated with 10 ng/μl TGF-β for 0 hr, 18 
hr, 24 hr, or 48 hr. Total cell lysates were then analyzed for expression of NFAT, D-type cyclins and 







Pancreatic cancer is the 4
th
 leading cause of cancer-related death in western 
countries. The number of diagnoses per year equals the number of deaths per 
year, making it the deadliest of all malignancies.  This is due in part to the low rate 
of respectability at presentation and very aggressive tumor behavior with an 
overall dismal prognosis. Although surgical resection is the only treatment method 
which offers the possibility of a cure, there are only a handful of long-term 
survivors. The poor survival of this malignancy has stimulated a wealth of research 
efforts into understanding the molecular mechanisms responsible for this disease. 
Results of these efforts have led to the discovery of the role of many molecular 
signalling systems involved in pancreatic carcinogenesis (Friess et al., 1999).  
 
The transforming growth factor-β (TGF-β) pathway is one of the signalling system 
that has been identified as a major contributor (Ghaneh et al., 2009; Friess et al., 
1993). TGF-β is an important cytokine that is involved in an extraordinary range of 
biological processes. At its discovery in 1983, it was given its malevolent moniker 
as a ‘transforming’ factor because of its ability to transform rat fibroblasts (Anzano 
et al., 1983; Chin et al., 2004). However, it is now known that TGF-β is a very 
helpful cytokine and actually is one of the most potent inhibitors of cellular 
proliferation in normal cells. Although limiting cellular proliferation is one of the 
primary functions of the TGF-β-signalling pathway in normal epithelial cells, 
numerous other cellular responsibilities have been identified, including but not 
limited to embryogenesis, differentiation, apoptosis, angiogenesis, 
immunosuppression and wound healing (Massague et al., 2000).  
 
The growth inhibiting functions of TGF-β are mainly based on its potential to 





Although TGF-β can stop cell cycle transition at any point, these responses are 
only effective at inhibiting cell cycle progression during G1. Specifically, TGF-β is 
able to prevent this progression by inducing the expression of the cyclin kinase 
inhibitors such as p15, p21, and p27 among others (Polyak et al., 1994; Datto et 
al., 1995; Hannon et al., 1994). These inhibitors block cyclins and CdKs from 
phosphorylating Rb and thereby inhibiting G1/S progression. In addition to 
controlling cell cycle progression through the induction of cyclin kinase inhibitors, 
TGF-β also directly suppresses mitogenic c-myc expression (Pietenpol et al., 
1990a; Pietenpol et al., 1990b). c-Myc is a ubiquitous promoter of cell growth and 
proliferation and its transcriptional downregulation is a rapid and general effect 
observed in most cells with an antiproliferative response to TGF-β. c-Myc levels 
must be low in order for powerful cyclin kinase inhibitors to become activated by 
TGF-β, since normally c-myc binds to the promoters of the cyclin kinase inhibitors 
(P15, P21 etc.) thus preventing their activation (Seoane et al., 2004). In most 
epithelial cells, including pancreatic ductal cells, TGF-β leads to the repression of c-
Myc levels and the expression of cyclin kinase inhibitors, which in combination, 
achieve substantial inhibition of the G1 to S phase progression (Dang et al., 1999).  
 
During carcinogenesis, most epithelial tumors cells change their responsiveness to 
TGF-β, escape from growth inhibition and instead respond with a more aggressive 
phenotype (Bachman et al., 2005; Tang et al., 2003). Much of our current 
understanding of this duplicitous role of TGF-β has been carried out in models of 
skin carcinogenesis where it has been best established (Li et al., 2005; Wang et al., 
2001; Li et al., 2006). Although the exact detailed mechanisms of this functional 
switch and its regulation remain to be elucidated, overexpression of the TGF-β is 
commonly implicated. Most cancer cells secrete larger amounts of TGF-β than 
their normal cell counterparts, and this overexpression is strongest in the most 
advanced stages of pancreatic and other malignancies (Derynck et al., 1985; 





Overexpression of TGF-β induces epithelial to mesenchymal transition (EMT) of 
normal and transformed epithelial cells and thus an enhanced proliferation and 
the migratory ability (Ellenrieder et al., 2001). This increased migration by 
epithelial cells that have undergone EMT is mediated by repression of cell–cell 
adhesion proteins, such as E-cadherin, and the induction of invasion-associated 
integrins and integrin-binding proteins. On the morphologic level, EMT results in 
the formation of highly aggressive, totally fibroblastic spindle carcinoma that have 
lost all the molecular markers of epithelial cells (Elliott et al., 2005). Changes in 
motility elicited by cytoskeletal re-organization, and enhanced secretion of matrix-
remodeling enzymes are classically considered the main driving forces in the 
contribution of reversible TGF-β-driven EMT to invasion and metastasis  (Derynck 
and Zhang et al., 2003; Ellenrieder et al., 2008, Yu et al, 2002). 
 
In pancreatic cancer, TGF-β mediated EMT is also closely associated with a strong 
promotion of cancer cell growth, although the molecular mechanisms underlying 
this phenomena are basically unknown. With the goal to dissect the mechanisms 
behind TGF-β’s ability to regulate these two opposing effects on pancreatic cancer 
cell growth, we conducted the presented study and uncovered a novel 
transcriptional pathway that mediates the TGF-β-growth switch from a suppressor 
to a promoter of cell proliferation. We initially demonstrated the growth 
stimulatory potential of TGF-β, which was apparent after 24hr and reached 
significance after 48hr post treatment. Growth stimulation was based on 
accelerated G1/S phase transition of the cell cycle and reflected by increased 
expression of D-type cyclins (cyclin D1 and cyclin D3) and their corresponding 
kinase partners CDK4 and CDK6.  
 
Most importantly, growth stimulation by the growth factor was dependent on a 
sustained induction of the c-Myc oncogene.  In fact, we provide strong evidence 





function is essential for subsequent G1 cell cycle transition, as evidenced by 
knockdown experiments. Detailed analysis of c-myc promoter regulation further 
showed that TGF-β targets a short promoter element that was previously 
described as the core element in promoter silencing by TGF-β. This core element, 
called TGF-β inhibitory element (TIE) is located between –84 and -63 relative to 
the P2 transcription initiation site (Chen et al., 2001) is essential for promoter 
repression. Extensive promoter analysis studies have demonstrated that in growth 
inhibited epithelial cells, TGF-β represses the c-Myc/TIE element through a TTGG-
core sequence, which combines an E2F-binding site with a Smad (GCTT) 
interacting motif. Site directed mutagenesis revelead that c-Myc repression is 
mediated by Smad3 bound repressor complexes. Smad3 interacts with p130 and 
E2F4 co-repressor proteins, binds to the TIE element and silence the promoter 
activity in order to block cell cycle transition (Chen et al., 2001). 
 
Our group have recently uncovered an alternative route of c-Myc suppression that 
is mediated by Smad3 interaction with the Sp1/KLF like transcription factor KLF11. 
KLF11 itself is induced by TGF-β and then binds to nuclear Smad3 (Buck et al., 
2006). Both factor form complexes in response to TGF-β and repress the c-Myc 
promoter through interaction with the TIE element, again underscoring the 
outmost importance of this promoter regulatory region. We now provide evidence 
that TGF-β aims at the identical c-Myc/TIE promoter sequence to promote 
pancreatic cancer cell growth, in this case however, to stimulate rather than 
suppress the promoter. On the molecular level, TGF-β induced the c-Myc 
promoter through the NFAT signalling and transcription pathway.  
 
NFAT proteins a family of transcription factors, comprises five members four out 
of them are Ca
2+
/calcineurin regulated proteins and one of them is NFAT5 
(TonEBP: tonicity element binding protein), which is regulated by hyperosmotic 





activated T cells (NFAT) has originally been identified as an inducible nuclear factor 
which binds to, and upregulates transcription from, the interleukin-2 (IL-2) gene 
promoter in T cells following stimulation of the T cell antigen receptor. Following 
their initial discovery, a multitude of studies quickly established that NFAT 
proteins are expressed not only in T cells, but many different cells of the immune 
system, and that signalling through NFAT proteins is crucial for the development 
and function of the immune system (Feske et al., 2003; Macian et al., 2005).  
 
In resting cells, NFAT is located in the cytoplasm as a hyperphosphorylated, 
inactive form. Under these conditions, NFAT phosphorylation is insured by the 
combined action of several maintenance kinases, including CK1 and DYRK2 that 
target specific serine residues in the NFAT conserved regulatory domain (Rao et 
al., 1997). Signalling through calcium/calcineurin results in calcineurin-dependent 
dephosphorylation of NFAT proteins, allowing their subsequent nuclear 
translocation, where they bind to their specific DNA binding 9 base pair element 
having consensus nucleotide sequence (A/T)GGAAA(A/N)(A/T/C)N to regulate the 
transcription (Rao et al., 1997; Medyouf & Ghysdael 2008). Since NFAT proteins 
bind their DNA target sequences only with relatively weak affinity, they regulate 
many, and probably all, of their target gene promoters in cooperation with 
partnering transcription factors.  
 
NFAT transcription complexes thus can be seen as integrators of signals from 
different pathways, where one signal must Ca2+/calcineurin, while the other 
signal(s) may be from divers other pathways. This also explains, in part, the broad 
diversity of cellular responses that Ca2+ signalling triggers depending on the cell 
type or the state of cellular differentiation and/or activation in cells inside or 
outside of the immune system (Crabtree et al., 2002). Recent studies have 
demonstrated that the vital role of NFAT signalling is indeed not restricted to the 





the development and differentiation of numerous mammalian cells and tissues 
(Horsley and Pavlath, 2002; Pavlath and Horsley, 2003). It has been shown, for 
instance, that NFAT proteins control multiple steps in myogenesis, chondrocyte 
differentiation and the development of the cardiovascular system (Chang et al., 
2004; Friday et al., 2000; Graef et al., 2001; Graef et al., 2003). In addition, recent 
evidence suggests that NFAT proteins, and in particular NFATc1, regulate 
important cellular processes such as proliferation and apoptosis in different cell 
types including epithelial cells, fibroblasts and preadipocytes (Hogan et al., 2003; 
Neal et al., 2003; Viola et al., 2005). For instance, growth stimulatory effects of 
NFATc1 and NFATc2 have been demonstrated in skeletal muscle (Pavlath et al., 
2003; Horsley et al., 2003) and heart valve development (Ranger et al., 1998; de la 
Pompa et al., 1998). 
 
Furthermore, NFAT transcription factors have been shown to control peripheral 
vascular development during angiogenesis, and to play roles in apoptosis 
regulation both in immune and nonimmune cells (Graef et al., 2001; Hernandez et 
al., 2001; Zaichuk et al., 2004). The broad spectrum of NFAT mediated processes 
and the central importance for growth and differentiation of many different cells 
and tissues strongly implicates a distinct oncogenic potential of NFAT transcription 
factors. Of special interest in this context is the role of Ca2+/calcineurin/NFAT 
signalling in cell cycle control, since calcium signalling has been shown to promote 
cell cycle progression and G1/S phase transition in a variety of normal cells as well 
as transformed cells (Lipskaia et al., 2004; Buchholz et al., 2006). 
 
Moreover, it has been demonstrated that overexpression of a constitutively active 
NFATc1 mutant is sufficient to induce a transformed phenotype in preadipocyte 
3T3-L1 fibroblasts, associated with altered expression of cell-cycle related genes 
such as cyclin D1, cyclin D2 and pRB (Neal et al., 2003). NFATs are also implicated 





NFATc1 is found in cases of Burkitt’s lymphoma, diffuse large B cell lymphoma and 
aggressive T cell lymphoma. In experimental settings of T cell acute lymphoblastic 
leukaemia (T-All), NFAT activation is calcineurin-dependent and pharmacological 
inhibition of calcineurin reverses cell growth and induces apoptosis (Mancini et al., 
2009). Consistent with these findings, the inhibition of calcineurin causes disease 
regression in mouse models of leukemia (Medyouf et al., 2008).  
 
Our laboratory have recently demonstrated that NFATc1 and NFATc2 are 
ectopically expressed and highly activated in pancreatic cancer cells in vivo and in 
vitro (Koenig et al., 2009). In immunohistochemical analyses, more than 85% of 
human pancreatic cancer specimens and all of the seven pancreatic cancer cell 
lines analyzed displayed strong nuclear staining for at least one of the two 
members. We now describe a critical function of NFATc1 and NFATc2 transcription 
factors in pancreatic carcinogenesis and demonstrate that the induction and 
activation of both proteins is essential for TGF-β to switch from a growth 
suppressor to an inducer of cancer cell proliferation. TGF-β induces in a calcineurin 
dependent manner the transcription of both proteins, which in turn function as 
downstream effectors to induce c-Myc transcription and cell cycle progression in 
cancer cells. Site directed mutagenesis combined with overexpression and 
knockdown studies revealed that NFAT proteins accumulate in the nucleus upon 
TGF-β stimulation and then target the c-Myc promoter to induce its expression. 
NFAT factors bind to the c-Myc/TIE element and displace Smad3 repressor 
complexes from the promoter, as evidenced by chromatin immunoprecipitation 
assays and reporter gene experiments, and this is ultimately linked with a strong 
induction of c-Myc expression in cancer.  
 
Thus, these findings have several important implications. First our results support 
the idea that pancreatic cancer cells can lose their ability to respond to TGF-β with 





show that TGF-β can signal simultaneously through different and opposing sets of 
intracellular pathway, e.g. the NFAT and the Smad pathway. In fact, Smad 
repressor complexes are still operative in cancer cells without inactivating 
mutations of the pathway, and thus can act on the c-Myc promoter to silence 
gene expression. However, stimulation with TGF-β induces activation of the pro-
proliferative NFAT cascade and these factors terminate Smad mediated repression 
through displacement from the promoter. Third, these results strongly suggest 
that the growth promoting properties of TGF-β are Smad independent and require 
sufficient activation of non-Smad signalling pathways, such as the calcium 




Figure 31.  Diagrmatic representation of TGF-β mediated growth promotion in cancer cells. 
Diagram showing TGF-β mediated pancreatic cancer cell proliferation via NFAT dominancy on c-













5.1 SIGNIFICANCE OF MY WORK: 
 
Work over the last years has considerably increased the knowledge about the 
molecular mechanisms implicated in the TGF-β signal transduction pathway. At a 
first glance, the TGF-β pathway seems quite linear, but it is turning to be complex, 
finely regulated and integrated with other signalling pathways. Due to its strong 
anti-proliferative and apoptotic effects on epithelial cells, TGF-β is considered a 
tumor suppressor and this function is clearly dependent on the Smad-signalling 
cascade (Chen et al., 2002). During cancer progression, tumor cells evade from 
TGF-β action either by acquiring mutations in components of the TGF-β pathway 
or by selectively inhibiting its anti-proliferative response (Massague et al., 2008). 
In the latter case, TGF-β not only loses its anti-tumoral function but can also 
become an oncogenic factor inducing proliferation, angiogenesis, invasion, 
metastasis and immune suppression (Seoane et al., 2006). 
 
This is the first report demonstrating that TGF-β directly induces the promoter of 
NFAT transcription factors, leading to increased expression and activation, and 
results in nuclear accumulation. Even more importantly, following activation NFAT 
factors bind to and stimulate transcription from the proximal c-Myc promoter and 
this is a key event in stimulation of G1/S phase cell cycle transition in cancer. The 
most important finding, however, is that NFAT operate through the same 
promoter sequence that has been identified previously as the core region in c-Myc 
promoter silencing. Mechanistically, NFAT must displace Smad3 repressor 
complexes from the proximal c-Myc promoter to bind and transactivate 
transcription.  
 
Together, this work significantly contributes to a better understanding of TGF-β 
growth promotion and the underlying transcriptional mechanisms. Moreover, we 





transcription factors that work downstream and compete with Smads on target 
promoters to drive the expression of genes important for cell cycle stimulation. 
Finally, our data also provide a platform for the development of novel strategies in 
pancreatic cancer therapy which are based on specific targeting of NFAT factors. 
Ongoing animal studies in our laboratory will show whether NFAT inhibition is an 
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